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Background: The gut microbiome plays a key role in metabolic disease development. Diet is a 
modifiable factor that significantly influences gut microbial composition, and fermented foods 
are a reliable source of probiotic microorganisms that can contribute to gut homeostasis. The 
primary objective of this study was to explore the feasibility of fermented vegetable 
consumption for six weeks on markers of inflammation and gut microflora profiles in women. 
Methods: Thirty-one women consumed 100 g/day of fermented vegetables (group A), non-
fermented vegetables (group B), or no vegetables (group C) for six weeks. Dietary intake was 
assessed twice during the intervention by a food frequency questionnaire. Participants provided 
fasting blood samples and stool samples before and after the intervention. Next-generation 
sequencing of the V4 region of the 16S rRNA gene was performed on the Illumina MiSeq 500 
platform. Nonparametric tests were used to analyze the data.  
Results: Participants’ ages ranged between 18 and 69 years. Compliance with vegetable 
consumption was 82% and 87% in groups A and B, respectively. We found 28 significant 
Pearson’s correlation coefficients between diversity and diet and metabolic biomarkers. There 
were no significant changes in levels of inflammatory markers among groups. At timepoint 2, 
Group A showed an increase in Faecalibacterium prausnitzii (P=.022), a decrease in 
Ruminococcus torques (P<.05), and an upward trend in alpha diversity measured by the 
Shannon index (P=.074).  
Conclusions: This suggests that regular consumption of fermented vegetables may shift gut 
microbiota towards a more beneficial composition. Further feeding trials test the role of regular 
consumption of fermented vegetables on metabolic markers and the gut microbiome are needed 




Chapter One: Literature Review 
1. Introduction 
1.1.  The Gut Microbiome 
The gut microbiome may be referred to as the collective entity of genes, microbes, and their 
metabolites present in the gut, whereas gut microbiota is the group of microscopic organisms 
present in the microbiome.1,2 We now know microbiome homeostasis relies on the symbiotic 
relationship between the host and bacteria, archaea, viruses, protozoans, fungi, and metabolites 
such as vitamins, amino acids, short-chain fatty acids (SCFAs) and that imbalances in gut 
homeostasis may lead to inflammation and disease.3 The gut microbiome is fundamental to 
human health and a deep understanding of interplay between microbes and host is of significant 
medical importance to understand disease development and treatment options. 
1.1.1.  Composition 
In 2008, the Human Microbiome Project (HMP) was funded by the National Institutes of 
Health to begin a well-organized, comprehensive catalogue of reference genomes of the 
intestinal microbiota and their communities through metagenomic analysis to identify 
taxonomic and functional information for disease intervention.4–7 Various metagenomic 
analysis strategies, such as analysis of the bacterial 16S ribosomal RNA (rRNA) gene, are used 
to identify and sequence gut microbiota. The 16S rRNA gene is present in all bacteria, and 
analysis of its subregions provides estimates of microbiota composition and diversity.2 Over 
100 trillion (1014) microorganisms, containing approximately 2172 bacteria species, over 200 
genera, and 12 phyla have been found to inhabit the human gastrointestinal (GI) tract. Out of 
the 12 phyla that make up the human microbiota, Bacteroidetes, Firmicutes, Proteobacteria, 
and Actinobacteria are the dominate phyla with Bacteroidetes and Firmicutes comprising about 




Table 1: Examples of Taxonomic Gut Microbiota Composition of the Predominate Four 
Phyla.10,11 
Phylum Bacteroidetes Firmicutes Proteobacteria Actinobacteria 
Class Sphingobacteriia, 
Bacteroidia 

















































The intestinal microbial composition not only varies throughout different GI tract areas, but 
also changes throughout the lifespan of an individual with mode of delivery, genetics, disease, 
age, lifestyle, antibiotic/medication use, and diet as the main influencing factors.11–22 Intestinal 
microbiota begin to develop before birth likely from a combination of maternal diet, mother's 
pre-pregnancy weight and weight gain during pregnancy, gestational age, genetics, and 
environmental factors.23 Mode of delivery (vaginal vs C-section) also influences infant gut 
microbiota with vaginal delivery resulting in an infant’s microbiota that most closely resembles 
its mother (72% vs 41%). Rapid colonization of the gut begins after birth.2 A neonate 
demonstrates an intestinal microflora of low diversity that is dominated by Proteobacteria and 
Actinobacteria. During infancy, microbial diversity increases and shifts resulting in Firmicutes 
and Bacteroidetes as the dominant phyla. Diet and environment continue to influence major 
microbial shifts until about 3 years of age when the child's microbial composition more closely 
resembles an adult-like profile.24 Major changes in gut microbiota continue throughout life 
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with common gut microbiota profiles occurring among four different age groups; young (22-
48 years), elderly (65-75 years), centenarian (99-104 years), and semi-supercentenarian (105-
109 years).25 The elderly population have increased amounts of Bacteroidetes and Clostridium 
cluster IV as compared to the young adult population, and the centenarians show decreased 
diversity with an abundance of facultative anaerobes (such as Escherichia coli) and shift in 
butyrate producers (such as a decrease in Faecalibacterium prausnitzii).2 As the body ages, 
physiological differences occur such as changes in acid secretion by the gut mucosa and a 
greater gut permeability that have been linked to increased circulation of antibodies to the 
intestinal microflora that result in alterations of gut microbiota composition.26 A small number 
of studies have demonstrated a gender difference in the gut microbial composition of men and 
women; however, these findings are inconsistent.27–32 
1.1.2.  Functions 
Also known as a “superorganism”, the gut microbiome has a significant influence on health.11 
Research suggests that high gut microbial diversity helps achieve and/or maintain gut 
homeostasis by improving gut microbiome functions that reduce risk of disease.13,33,34 The 
overall functions include metabolic, protective (immune and barrier), and trophic.2,35 
1.1.2.1.  Metabolic functions 
1. Energy production from nutrient biotransformation. The gut microbiota extract energy 
from the fermentation of nondigestible polysaccharides and oligosaccharides into 
short-chain fatty acids (SCFAs).35 SCFAs are the primary energy source for colonic 
cells and provide approximately 500-1200 calories per day for the human host36 with 
the most of the calories getting utilized by the microbiota.37 SCFAs are known 
influencers of energy metabolism and intake.38,39  
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2. Conversion of nitrogenous compounds into microbial protein such as the conversion 
of L-histidine to histamine and glutamate to g-amino butyric acid (GABA).35  
3. Breakdown of various inactive dietary polyphenols into active compounds that the 
body can use. For example, “the conversion of inactive isoflavones to the aglycon 
equol, which has antiandrogenic and hypolipidemic effects”.35  
4. Synthesis of vitamins B and K to extrapolate their immunomodulatory properties.35,40  
5. Xenobiotic and drug metabolism, which may significantly influence disease therapy. 
For example, Eggerthella lenta from the Actinobacteria phyla inactivates digoxin.35  
6. Positive influences on lipid metabolism via modulation of lipogenesis and fatty acid 
oxidation.35  
1.1.2.2.  Protective functions 
In pre-clinical and clinical research, Akkermansia muciniphila supplementation has 
demonstrated a reduction in lipopolysaccharides (LPS), improved glucose metabolism, and 
improved hepatic inflammatory markers; thus, contributing to reduced inflammation and 
improved gut barrier function.41–45 Commensal gut bacteria have been observed to promote the 
migration and function of neutrophils as well as the differentiation of the T cell population into 
the various types of T helper cells that help control inflammation and promote immune 
homeostasis through modulation of cytokines such as interleukin-22 (IL)-22, IL-17A, and IL-
17F.18 Several bacterial species Clostridium ramosum, Eggerthella lenta, Coprococcus 
eutactus, Lactobacillus casei, Leuconostoc mesenteroides, and Bacteroides uniformis, and are 
associated with the expression of proinflammatory immunoglobins such as IgA and IgE that 
increase production of cytokines46 such as IL-10, IL-4, transforming growth factor beta (TGF-
), and IL-6.47 Akkermansia muciniphila has demonstrated that gut microflora exert 
antimicrobial functions by stimulating the release of various lectins with antimicrobial 
properties such as RegIIIc, -defensis, and angiogenins that are secreted in response to 
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potential bacterial infections. These lectins function by decreasing the secretion of IL-17 that 
plays an important role in the onset of irritable bowel disease (IBD).48 Also, the synthesis of 
SCFAs reduces the pH of the intestinal lumen that provides inhibition against intestinal 
pathogens,49  prevention of pro-inflammatory bacterial translocation, and maintenance of gut 
epithelial barrier protection.39 SCFAs such as butyrate have been observed to bind to G-protein 
coupled receptor 4 (GPR4) inhibiting the activation of the nuclear factor-kappa beta (NF-B) 
pathway that is typically activated during inflammation. The binding of SCFA to GPR43 is 
one of the pathways that has been observed to regulate immune responses in the gut.50 The 
production of extracellular polysaccharides by bacterial strains has immunomodulatory effects 
by shielding the intestinal lining from inflammatory factors such as the antimicrobial peptide 
LL-37 and IL-17; thereby, preventing the occurrence of inflammatory processes that might be 
caused by antigens from foreign bacterial particles.51,52 The production of polysaccharide A 
provides significant anti-inflammatory effects in the gut through the activation of regulatory T 
cells.50 Gut homeostasis provides structural integrity of the gut barrier that protects against 
colonization of pathogens into the GI tract and translocation of microbiota into circulation; 
thus, preventing a systemic infection.35 The compartmentalization of the gut microbiota is 
performed by lamina propria macrophages. The macrophages perform this function by 
phagocyting commensal gut microorganisms that penetrate the intestinal epithelial cell barrier. 
Bacteria that succeed in penetrating the intestinal epithelial cell barrier are engulfed by 
dendritic cells that reside in the intestinal mucosa.53  
1.1.2.3.  Trophic functions 
Many trophic functions that contribute to the development of the immune system occur as a 
result of cross-talk between the gut microbiota and its host’s immune system. Gut microbiota 
can modulate epithelial cell proliferation and differentiation, intestinal motor activity, 
induction and homeostatic regulation of adaptive immunity, and neuroendocrine pathways. 
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Cross-talk can induce regulatory T cells that increase the host’s tolerance to gut antigens; thus, 
preventing inflammation.54 Specifically, B. lactis has demonstrated an increase of peripheral 
blood leukocytes and natural killer cells that play a prominent role in the recognition and 
destruction of pathogenic viruses, bacteria, and tumor cells.55  
1.1.3.  Short Chain Fatty Acids 
As metabolites of species such as Bacteroides, Bifidobacterium, Streptococcus, Coprococcus 
catus, Anaerostripes, Roseburia, Salmonella, Dalister, Ruminococcus, and Faecalibacterium 
prausnitzii,56 SCFAs (butyrate, acetate, and propionate) are key players in microbiome health 
due to their role in metabolic (i.e. glucose, lipid, appetite, and pancreatic) and immune 
regulation.39,57,58 Mostly, SCFAs have positive correlation with health benefits; however, 
overproduction of SCFAs has promoted adverse health reactions.57–61 For example, butyrate is 
essential in the pathogenesis of IBD due to its anti-inflammatory effects,21 but in high 
concentrations, it has been positively correlated to obesity and insulin resistance. Perhaps these 
correlations are related to various concentrations of SCFAs and/or their absorption capability 
in the gut.57,59,60  
1.1.4.  Dysbiosis  
Dysbiosis refers to an imbalance of gut microflora62 that is associated with diseases such as 
such as obesity,63,64 IBD (colitis and Crohn’s disease)65–68 irritable bowel syndrome (IBS),69,70 
celiac disease, metabolic disease, cardiovascular diseases,50,71 and fatty liver disease.74,75  
Initially thought to arise from an increased Firmicutes to Bacteroidetes ratio, it is now known 
that dysbiosis can occur as a result of changes in other gut microbiota species as well.8,77,78 
Koliada and colleagues79 demonstrated that obesity is positively correlated with higher levels 
of Firmicutes and lower levels of Bacteroidetes as compared to those of normal weight. 
Furthermore, obese individuals have elevated levels of pro-inflammatory cytokines and a less 
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diverse microbiota as compared to healthy subjects.80,81 Million et al81 reported an increase in 
Lactobacillus reuteri and a decrease in Bifidobacterium animalis in obese subjects relative to 
healthy volunteers.81 A study by Farup et al82 that aimed to highlight the gut-brain axis, 
examined psychobiological disorders in morbidly obese adolescents and found that 
approximately 62% of the study subjects had dysbiosis along with significant abdominal 
complaints such as food intolerance that were scored using the IBS Severity Score system.82 
However, new research by Magne and colleagues64 proposed that the influx of studies reporting 
that a higher Firmicutes to Bacteroidetes ratio is a marker of obesity-related dysbiosis may by 
inaccurate. Discrepancies in supporting research may be explained by, interpretative bias, 
methodological differences, poor characterization of recruited subjects, and/or lifestyle 
variables known to affect microbiota composition. The highly variable relative abundances 
(RA) of Firmicutes and Bacteroidetes across participants is likely related to the multitude of 
microflora-related diet and lifestyle factors and the inadequate stratification of patients in 
subgroups that makes this obesity biomarker less convicing.64 
A study conducted on type 1 diabetic children showed a reduction in gut microbiota 
diversity with an unfavorable Firmicutes/Bacteroidetes ratio in the participants’ stool 
samples.83 Studies conducted by de Goffau84 demonstrated that pre-diabetic children with 
antibodies against -cells showed an increased number of Bacteroides with a decrease in lactate 
and butyrate producing bacteria being observed in the study subjects compared to healthy 
controls.60  
Several studies have correlated microbiota with type 2 diabetes.85–88 A recent study by 
Zhao et al88 compared the gut microflora of 65 type 2 diabetic (T2D) patients, 49 with diabetic 
complications and 16 without complications, and 35 healthy controls. Through 16S mRNA 
analysis of fecal samples, these authors found the RA of Proteobacteria and the 
Firmicutes/Bacteroidetes ratio was higher among the T2D patients as compared to the control 
8 
 
subjects. Furthermore, the T2D patients also showed significant disorders in SCFAs, bile acids, 
and lipids when compared to the control subjects. For example, the abundances of the SCFA 
producers, Lachnospiraceae and Ruminococcaceae were significantly increased among the 
T2D patients suggesting that these bacterium families have other functions than just SCFA 
production. The genera Bacteroides and Prevotella were significantly lower in the control 
group, but Prevotella species were increased in obesity and hypertension subjects. Altogether, 
44 microbes of various taxa were identified to have significant correlations with the metabolic 
traits of body mass index (BMI), blood glucose levels, blood pressure, blood cholesterol, fecal 
bile acids, and fecal lipids.88 Moreover, Bifidobacteria have a potential role in improving the 
maintenance and remission of mild-to-moderate ulcerative colitis (UC) along with the 
prevention of pouchitis relapse, IBS, constipation, antibiotic-associated diarrhea, necrotizing 
enterocolitis (NEC), colorectal cancer, and non-alcoholic steatohepatitis (NASH) among 
several other extra-intestinal diseases such as cardiovascular disease and psychiatric 
disorders.76  
1.2.  The Gut Microbiome and Inflammation 
Through a symbiotic relationship, gut microbiota play a fundamental role in the induction and 
function of the innate and adaptive immune system.89 Inflammation begins when cell surface 
receptors react to adverse stimuli that trigger inflammatory pathways.90 Dysbiosis stimulates 
inflammation due to an imbalance of commensal and pathogenic bacteria in addition to the 
production of microbial antigens and metabolites that activate tissue-resident macrophages 
contributing to metabolic diseases such as diabetes, obesity, and metabolic syndrome.3 
Macrophages 1 (M1) and 2 (M2) are two major inflammatory phenotypes. M1 is signaled by 
LPS and T helper 1 (proinflammatory) cytokines, whereas M2 phenotype is triggered by T 
helper 2 (allergic) and anti-inflammatory cytokines.3 Some inflammatory biomarkers such as 
cytokines, LPS, lipopolysaccharide-binding protein (LBP), tumor necrosis factor alpha (TNF-
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α) and C-reactive protein (CRP) have been used in the research of dysbiosis-related disease.91–
97 
1.2.1.  Cytokines 
During inflammation, macrophages and adipocytes secrete inflammatory cytokines.98 
Cytokines are pleiotropic signaling proteins that regulate many biological functions such as 
inflammation, immunity, hematopoiesis, and cellular proliferation and differentiation. 
Extensive research has highlighted cytokine's involvement in disease pathogenesis and 
immune homeostasis.99 Cytokines act by binding to a receptor that sends a signal to the 
recipient cell causing a change in function. Types of cytokines include interferons (IFN), 
interleukins (IL), adipokines, transforming growth factors (TGF), and tumor necrosis factors 
(TNF). Cytokines are classified according to the cell type that secretes them. Lymphokines 
such as IL-17, IL-17F, IL-22, IL-10, IFN-γ, TGF-β, IL-1, IL-2, and, TNF-α are secreted from 
lymphocytes such as T cells that regulate immune responses to antigens. Growth factors such 
as TGF-β promote cell survival. Chemokines such as CCL2, CCL9, CCL10, CCL11, IL-8 are 
chemotactic for inflammatory cells. Proinflammatory cytokines such as IL-1, IL-6, IL-8, TNF-
α, TNF-β, IFN-γ amplify the inflammatory process, whereas anti-inflammatory cytokines such 
as IL-10, IL-11, IL-13, granulocyte-macrophage colony stimulating factor (GM-CSF), and 
TGF-β attenuate the inflammatory response. However, some cytokines such as IL-4, IFN-γ, 
and GM-CSF are bi-functional and show stimulatory and inhibitory effects. Research shows a 
significant association between dysbiosis and increased levels of TNF-α and IL-6.93 A 
comprehensive study by Schirmer and colleagues91 demonstrated that gut microbiota 
composition is linked to cytokine production. 
1.2.2.  Tumor Necrosis Factor-Alpha 
Gut microbiota also play an important role in TNF-α response.92 TNF-α, a pro-inflammatory 
cytokine mainly produced by adipocytes and macrophages,100 regulates cell survival through 
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cell proliferation, differentiation, and apoptosis.101 Known for its role in initiating an 
inflammatory cytokine cascade, TNF-α signals through the two transmembrane receptors TNF 
receptor 1 (TNFR1) and TNF receptor 2 (TNFR2). While both receptors are important for 
cytotoxicity and NF-κB activation, TNFR1 is more responsible for cell growth and TNFR2 is 
targeted towards lymphoid cell proliferation. Increased TNF-α production and TNF receptor 
signaling are correlated to the pathogenesis of many diseases such as Crohn's disease, diabetes, 
and obesity.101 
1.2.3.  Lipopolysaccharide (LPS) and Lipopolysaccharide-Binding Protein (LBP) 
The endotoxin LPS is a component of the outer membrane of many gram-negative bacteria 
found in the gut and is a crucial inducer of inflammatory responses.100,102,103 Chronically 
elevated LPS levels can cause metabolic endotoxemia that is a condition characterized by low 
grade inflammation, insulin insensitivity, and an increased prevalence of cardiovascular 
disease (CVD) and obesity.103–109 LBP, a biomarker of endotoxemia,97 is an acute phase protein 
that is mainly produced by the liver and helps mediate the biological actions of LPS. Research 
suggests that LBP may be a better inflammatory marker than LPS and may fill a "diagnostic 
gap" between other inflammatory markers.110–114 The LPS recognition by Toll Like Receptor 
4 (TLR4) is a critical pathway of the innate immune system. This pathogen-associated 
molecular pattern uses the key accessory proteins, LBP, CD14, and MD-2, for LPS to be 
recognized by TLR4 and result in a pro-inflammatory signaling cascade. First, LBP is needed 
to dissociate the LPS monomer from LPS aggregates such as micelles and carry the LPS 
monomer to a CD14 molecule. Then the CD14 molecule dissociates the LPS monomer from 
the LBP and facilitates the transfer of LPS to the TLR4/MD-2 receptor complex which leads 
to homodimerization of TLR4. This process causes dimerization of the cytoplasmic TIR-
domain (Toll-interleukin-1 receptor) that provides a binding site for MyD88 (myeloid 
differentiation primary response gene 88). Finally, the transcription factor NF-κB and MAP 
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(mitogen-activated protein) Kinase pathways are activated resulting in expression of pro-
inflammatory cytokines.115 Pro-inflammatory cytokines such as IL-6 and TNF-α are secreted 
from adipocytes; thus, showing how the LPS-mediated inflammatory response correlates to 
obesity.94 Research has found increased LPS and LBP levels among overweight and obese 
individuals as compared to normal-weight individuals,94,97,116–118 and that positive changes in 
gut microbiota can reduce these levels.97,117,119 
1.2.4.  C-Reactive Protein 
Dysbiosis is significantly associated with increased levels of CRP.93 CRP, an acute-phase 
protein that is synthesized by hepatocytes, is positively correlated with chronic inflammation 
and related diseases120,121 and is associated with the gut microbiota.122 A recent review by 
Munckhof et al122 concluded that the abundance of gut bacteria such as Bifidobacterium, 
Faecalibacterium, Ruminococcus, and Prevotella was inversely related to the inflammatory 
markers CRP and IL-6; thus, demonstrating the importance of bacterial changes in the 
microbiome for the modulation of systemic inflammation. Obesity and dysbiosis are correlated 
to increased CRP and LPS levels94,103,123 among individuals with and without 
diabetes.38,108,124,125 In a study conducted by Visser et al,123 increased CRP levels were found 
in overweight and obese subjects likely as a result of the release of IL-6 from adipocytes that 
mediate the synthesis and release of the CRP. 
1.3.  The Gut Microbiome and Diet 
Diet significantly affects gut microbiota throughout the lifespan of an individual.21,126–128 An 
infant’s diet of breast milk will tend to favor a simple intestinal microbiota with Bifidobacteria 
being the predominant bacteria while formula fed infants have enriched amounts of 
Bifidobacteria and Clostridia.126,129 Fiber has a significant impact on gut microbiome. Various 
types of plants have different chemical compositions, physicochemical properties, and fibers. 
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Plant-based foods contribute several types of fiber including prebiotic fibers such as β-glucan 
and pectins; thus, supporting a more diverse microbiota composition.130 Prebiotic fibers found 
in fermented and non-fermented vegetables contribute to the growth of probiotic bacteria as 
they move through the GI tract untouched until fermented by the colon.131,132 The International 
Scientific Association for Probiotics and Prebiotics (ISAPP) consensus panel proposed the 
most recent definition of prebiotic as, “A substrate that is selectively utilized by 
host/commensal microorganisms conferring a health benefit.”133 Moreover, this symbiotic 
relationship of pro- and prebiotics may be classified as a functional food.134 For example, 
research demonstrated that prebiotics may also reduce body fat through altering intestinal 
microflora among obese and overweight children.135 Another study noted that improved IBS 
symptoms after sauerkraut consumption were likely related to prebiotics rather than lactic acid 
bacteria strains.136 Salazar and colleagues38 reported that inulin-type fructan prebiotic 
promoted alterations in gut microbiota composition by selectively modulating Bifidobacterium 
spp. and decreasing fecal SCFA concentration in obese women. Thus, prebiotic consumption 
may decrease metabolic risk factors associated with higher fecal SCFA concentration in obese 
individuals.38 There exist striking differences in the microbiota of children living in rural Africa 
than their counterparts from Western Europe. Children from Burkina Faso, whose diet was 
principally composed of dietary fiber, had a high prevalence of Bacteroides that are specifically 
known to contain genes that encode for molecules that play a role in the hydrolysis of 
polysaccharides found in dietary fiber. Two other gut bacteria genera, Prevotella and 
Xylanibacter, were observed to be more prevalent in the African population than in the Western 
European population. Prevotella and Xylanibacter synthesize enzymes necessary for the 
hydrolysis of cellulose and xylan. Moreover, European children had significantly less SCFAs 
in their fecal matter than those in the African cohort.50 A polysaccharide-rich diet such as a 
low-fat/high-fiber diet is correlated with an increased amount of Actinobacteria and 
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Bacteroidetes and a decreased amount of Firmicutes, while the high-fat/low-fiber diet rich in 
sugar and animal protein is correlated with a significantly lower amount of Actinobacteria and 
Bacteroidetes.16,137 Vegans, vegetarians, and omnivores will have completely different 
microbiome profiles.20,21,138,139 The total amount of Bacteroides spp., Bifidobacterium spp., 
Escherichia coli, and Enterobacteriaceae spp. was lower in vegan fecal samples than in the 
control subjects. Maintaining a vegetarian diet results in a complete shift in microbiota 
diversity towards microbial compositions associated with health benefits.20,138,139 An 8-week 
randomized control trial of 82 healthy, overweight/obese subjects with metabolic disease risk 
factors such as habitually low fruit and vegetable intakes and sedentary lifestyles aimed to 
explore the effects of an isocaloric Mediterranean diet (MD) on the gut microbiome. Forty-
three participants consumed a MD diet with energy intake tailored to their typical dietary 
intake, and 39 participants functioned as the control group and consumed their typical dietary 
patterns. The MD group demonstrated decreased low-density lipoprotein, plasma cholesterol, 
inflammation, Ruminococcus gnavus (proinflammatory species) abundance, urinary carnitine 
levels, insulin resistance, and increased Faecalibacterium prausnitzii (SCFA-producing 
species) abundance, butyrate metabolism, urinary urolithins, and fecal bile acid degradation.140 
A Western-type diet that is high in animal protein and fat, and low in fiber, led to a decreased 
microbial diversity. Specifically, a decrease in the beneficial Bifidobacterium and Eubacterium 
species was noted.137,141 Furthermore, a preclinical study by Sonnenburg et al142 reported that 
a low fiber diet such as the Western diet causes a reduced gut microbiota diversity and that 
after many generations this may lead to extinction of some gut microbiota compounds. Humans 
who consume a large proportion of dietary fiber, including those who live in developing 
countries and rural areas, have lower incidences of inflammatory diseases such as IBD, colitis, 
and diabetes due to positive changes in gut microbiota.21,84,139,143,144 An animal-based diet was 
shown to increase bile tolerant microorganisms such as Alistipes, Bilophila, and Bacteroides, 
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and decrease Roseburia, Eubacterium rectale, and Ruminococcus bromii that metabolize plant 
polysaccharides.145,146 Furthermore, due to the high sulfur content of animal-derived protein 
and the H2S (hydrogen sulfide) toxin hypothesis, an omnivore’s diet may play a significant role 
in the pathogenesis of ulcerative colitis (UC). Consumption of high sulfur-containing 
compounds such as amino acids methionine, cysteine, and taurine largely found in animal 
proteins147 increases H2S production, increases sulfate-reducing bacteria such as Desulfovibrio 
spp., and alters the microbial community that may lead to an increased risk of IBD.66 
Additionally, the intestinal microbiota of omnivores was shown to synthesize significantly 
more trimethylamine-N-oxide (TMAO) from choline and L-carnitine, whereas vegetarians 
show a diminished capacity to produce TMAO as a microbial metabolite. Choline and carnitine 
are precursors of TMAO and are primarily found in foods of animal origin. High levels of 
TMAO is a risk factor for atherosclerosis and IBD.148–150  
In addition to long-term dietary patterns having longitudinal stability on gut 
microbiome composition, short-term dietary intake can cause rapid changes in composition.146 
For example, in a preclinical review, Delzenne et al151 reported that a high caloric intake 
promoted a rapid change in gut microbiota with an increase in Firmicutes and a decrease in 
Bacteroidetes within 24 hours. Zarrinpar and colleagues152 demonstrated daily cyclical 
fluctuations in composition related to the daily feeding/fasting cycle. For example, time-
restricted feeding (TRF) of nocturnal feeds resulted in Firmicutes as the most abundant 
bacterial species, while light-time fasting resulted in the lowest concentration of Firmicutes. 
Moreover, diet-induced obese mice showed a decrease in α-diversity of the gut microbiome, 
which can be protective against obesity, suggesting that diet-induced obesity hinders the daily 
feeding/fasting rhythm and according cyclical functions. Nocturnal TRF was shown to improve 
cyclical fluctuations and protect against metabolic diseases such as obesity. The fundamental 
mechanisms of the relationship between the feeding/fasting cycle and the gut microbiome are 
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unknown, however, nocturnal TRF was shown to increase gut microflora that influence host 
metabolism demonstrating that timely feeding patterns in addition to diet are important 
contributors to host metabolism.152 
1.3.1.  Fermented Foods 
Originally intended to preserve food, fermentation dates back thousands of years ago. The 
identification of microorganisms involved in fermentation was done by Van Leuwenhoek and 
Hooks around 1665.153,154 Circa 1877 Sir John Lister demonstrated the lactic acid bacteria, 
Lactococuus lactis, as the predominant species responsible for milk fermentation and 
consequently yogurt formation.154,155 Later, Louis Pasteur defined fermentation from the Latin 
word “Fevere” that means life without air. The discoveries regarding fermented vegetables 
coincided with Europe’s industrial revolution era that led to a population exodus from the rural 
to the urban areas. As a consequence, food production was involved in large scale 
preparations.154,156 As the production of fermented products improved to modern-day, large-
scale productions, the use of well-defined starter cultures became popular as the use of the 
undefined strains used in ancient times became less popular.154,157 However, several draw-
backs exist regarding this large-scale fermentation process. For example, nisin, a product of 
lactic acid bacteria, has been observed to inhibit the growth of other bacterial cultures needed 
for the fermentation process.154,158 Today, fermentation may be defined as, "Those foods or 
beverages made through controlled microbial growth and enzymatic conversions of major and 
minor food components."159 
The main components involved in the fermentation process include the following:  
microorganisms such as yeast and bacteria, organic material that needs to be fermented, a 
solution whereby fermentation will take place, and several tools that will be used to monitor 
and control the fermentation process.160 The fermentation process of vegetables is as follows: 
the vegetables are harvested, washed, and disinfected. Salt is added to the vegetables to create 
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a brine solution. Then, the vegetables are soaked in the brine solution and followed by the 
fermentation process that is carried out between 5-30 days at 25-30C. Drying and pressing are 
then carried out with the resulting fermented products being either pasteurized or packaged 
dry.161 When vegetables are sealed in a jar and undergo the fermentation process in a brine 
solution, the live microorganisms created increase their nutritional value162 and help restore 
gut microbial communities.163 For example, the lactic acid bacteria present in fermented 
vegetables release enzymes and vitamins that lower intestinal pH levels through lactic acid and 
folic acid.164 This not only results in increased bioavailability of folate, riboflavin, vitamin 
B12,165 and iron as the lactic acid bacteria help change iron into its more absorbable form 
(Fe3+),166 but also an increased calcium ion pool167 and amino acid synthesis.165 Specifically, 
pickled vegetables and fermented soybean (tempeh) have increased vitamin B levels,165 while 
“Tarhana” contains high concentrations of vitamins C, B3, B5, and B9.168,169 Sauerkraut not 
only has increased levels of vitamins C and B, but also increased levels of minerals such as 
calcium, iron, potassium, and phosphorous.169,170 Moreover, probiotic lactic acid bacteria 
contain high levels of lactase that when released into the intestinal lumen aids in digestion of 
ingested lactose, thereby relieving the symptoms of lactose intolerance.171 Fermented food 
consumption has demonstrated significant shifts in gut microbiota towards microbial 
compositions related to health-promoting functions.172–174 
Due to different fermentation processes, confusion exists over which fermented 
products actually contain live microorganisms (probiotics). Some commercial foods such as 
pickles and olives are not fermented at all, but instead placed in a brine solution under 
conditions that do not lead to fermentation. Additionally, processes such as thermal processing 
create an inhospitable environment for microbial populations. For example, sauerkraut is often 
cooked after fermentation causing the live organisms to be inactivated.175 However, even 
though some fermented vegetables no longer contain live bacteria, they remain great sources 
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of prebiotic fiber.131,176 Table 2 describes the methods of production, microorganism 
composition, and health benefits of four popular fermented vegetables.  





Method of fermentation Microorganism 
composition 
Health benefits 
Olives Spontaneous fermentation in 8 to 










Prevention of enteric 
infections such as listeria; 
reduction of cholesterol 
levels; good sources of 
vitamins A, B, and E.179 
Kimchi Shredded cabbage is brined in 8 
to 10% salt solution for 2 to 7 
hours. Addition of other 
vegetables such as onions and 
green pepper is carried with dry 
salt, placed in a fermentation 
vessel for 1 to 3 weeks at low 









Contain high levels of 
vitamin B, -carotene, 
dietary fiber, sodium, 





primary nutrients include 
vitamins A, vitamins B1, 
vitamins C, vitamins K, 
calcium, and niacin.182 
Sauerkraut Freshly shredded cabbage is 
brined in 0.7 to 2.5% sodium 
chloride solution. After salting, 
the cabbage is placed in a 
fermentation vessel that is tightly 
sealed in order to exclude air. The 
fermentation process occurs 
usually between 1 week to several 







Components in sauerkraut 
such as ascorbic acid and 
ascorbigen are known to 
decrease DNA damage 
and cell mutation rates in 
patients with cancer.187 
Sauerkraut is additionally 
rich in lactic acid bacteria 
that have been shown to 
aid in preventing lactose 
intolerance by producing 
lactase that aids in the 
digestion of lactose.158 
Sauerkraut increases the 
immune system’s ability 
to fight off pathogenic 





Pickles Pickled vegetables are submerged 
in a brine solution containing 
3.5% of sodium chloride solution. 
The pickling process is usually 
performed at low temperatures 
for up to two weeks’ time. 
Fermentation occurs in a loosely 
closed fermentation vessel in 
order to allow for the escape of 








Pickles mainly consist of 
vitamins such as vitamin 
A, riboflavin, niacin, and 
thiamin that help prevent 
anemia while lactic acid 
bacteria may help reduce 
diarrhea caused by 
microorganisms such as 
E.coli.191 Fermented 
pickles harbor many lactic 
acid bacteria strains with 
conjugated linoleic acid-




diabetic activities.193  
 
1.4.  Fermented Vegetables and Disease 
While increasing in numbers and popularity, there still exists limited human studies that have 
evaluated the effects of fermented vegetable consumption on gut microbial composition and 
inflammation. Additionally, most research has been conducted in Asian countries that 
primarily studied the effects of kimchi, miso, and natto.194 In addition to the research reported 
in Table 2, further discussion on the health benefits of soy, kimchi, and sauerkraut is presented 
below as there has been more research on these foods compared to other fermented vegetables. 
1.4.1.  Soy 
Consumption of fermented soy products such as fermented tofu, tempeh, miso, and natto has 
been shown to increase gut microflora diversity and demonstrate anti-obesity, anti-diabetic, 
and anti-inflammatory effects.194,195 In a cross-sectional study that used a validated food 
frequency questionnaire, Wu et al196 found that regular consumption of fermented soy was 
associated with reduced inflammatory markers such as IL-6, TNF-α, and soluble TNF receptors 
1 and 2 among Chinese women. Similarly, another cross-sectional study among Japanese 
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workers (men and women) found that fermented soy intake was associated with decreased IL-
6 concentrations in Japanese men.197 Stephanie and colleagues198 demonstrated that 100 mg of 
steamed tempeh led to increased concentrations of Akkermansia muciniphila and IgA among 
16 healthy participants (8 women and 8 men); thus, demonstrating tempeh’s potential role in 
immune function. A 2-week consumption of natto-containing miso soup among eight healthy 
participants improved gut microbiota compositions via increased abundances of Bacilli and 
Bifidobacteria, and decreased abundances of Clostridium perfringens and 
Enterobacteriaceae.199 However, non-fermented soy products have also demonstrated these 
properties. Research attributes soy's health benefits to several factors such as the prebiotics, 
probiotics, and isoflavones (genistein and daidzein) contained in soy products. More research 
is needed to decipher the impact of fermented soy versus non-fermented soy on health and the 
mechanisms involved.194,195,200 For example, a reduced risk of type 2 diabetes was associated 
with increased consumption of fermented soy foods that were rich in phytoestrogens and 
bioactive peptides. In combination with estrogen receptors, the isoflavonoids and proteins 
contained in fermented soybeans help alleviate some of the symptoms commonly associated 
with type 2 diabetes such as insulin resistance. Phytoestradiol found in soybeans is similar in 
structure to estradiol that binds to insulin receptors found at the surface of  cells; thus, they 
might play an important role in the regulation of insulin synthesis and secretion by the  cells201  
1.4.2.  Kimchi 
Kimchi is a traditional fermented food from Korea that consists mostly of the Napa cabbage 
variety. A cross-over study by Kim et al202 that included 22 overweight and/or obese subjects, 
assessed metabolic outcomes after consumption of 300 g per d (100 g/meal) of fresh or 
fermented kimchi for four weeks. Both groups showed a decrease in body weight. The 
fermented kimchi group, as compared to the fresh kimchi group, showed significant 
improvements in waist-to-hip ratio, fasting glucose levels, percent body fat, blood pressure, 
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and total cholesterol. Additionally, leptin, that is usually synthesized by genes associated with 
obesity, was elevated in obese subjects and positively correlated to insulin resistance. 
Fermented kimchi consumption was shown to have a net effect on the decrease in serum leptin 
levels in the study cohort. Circulating adhesion molecules such as vascular cell adhesion 
molecule (VCAM) and intercellular adhesion molecule (ICAM)-1 were tested due to their 
reported positive correlation with increased cholesterol levels in obese individuals with type 2 
diabetes. As such, activation of oxidative stress occurs leading to the attraction of inflammatory 
cells that in turn overexpress inflammatory factors that are commonly associated with the onset 
of type 2 diabetes. The effect of kimchi and its ability to decrease body weight was primarily 
correlated to a decrease in total cholesterol, leptin, and monocyte chemoattractant protein 
(MCP)-1 levels. However, there was no significant differences in the levels of proinflammatory 
cytokines such as CRP, TNF-, and IL-6 after consumption of fermented kimchi in the study 
subjects.202 These results were hypothesized to be from the increased proportion of lactic acid 
bacteria strains in the fermented kimchi as compared to fresh kimchi. 202 A randomized 
controlled study conducted by Han et al203 reported the contrasting effects of fresh versus 
fermented kimchi on the gut microbiota and gene expression related to the prevalence of 
metabolic syndrome in obese Korean women. Consumption of 180 g/d (60 g/meal) of 
fermented kimchi as compared to fresh kimchi led to improvements in gene expression profiles 
with regards to metabolism, immunity, and digestion. A decrease in Firmicutes and an increase 
in Bacteroidetes was observed after consumption of fermented kimchi. A direct correlation 
between increased Firmicutes and decreased Bacteroidetes among obese subjects as compared 
to their lean counterparts has been found by prior research. Bifidobacterium longum is one of 
the bacteria species found in fermented kimchi that is known to possess anti-obesity properties 
such as improvement of body weight, fasting glucose levels, and insulin sensitivity. 
Bifidobacterium longum levels increased with decreases in body weight and waist 
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circumference among the fermented kimchi group. Moreover, the Acyl‐CoA synthetase long‐
chain family member 1 (ASCL1) gene, known for its involvement in lipid metabolism and 
promotion of fatty acid degradation via AMP (adenosine monophosphate)-activated protein 
kinase metabolic pathway, and the aminopeptidase N (ANPEP) gene that functions in 
inflammation, apoptosis, and angiogenesis were significantly elevated in subjects that 
consumed fermented kimchi. Specifically, these authors hypothesize that the subjects with 
improvements in waist‐to-hip ratio, blood pressure, fasting blood glucose and insulin, and total 
cholesterol were correlated to the increased expression in these two genes.203 The ability of 
kimchi to improve the serum lipid profile in healthy young adults was also probed. Choi183 
demonstrated that total cholesterol, blood glucose levels, and low-density lipoprotein 
significantly decreased after seven days of intake of 15 g per d of fermented kimchi. 
Lactobacillus acidophilus that is predominantly found in fermented kimchi has been shown to 
exert its cholesterol lowering properties by binding to cholesterol in their cell wall leading to 
decomposition for assimilation in the gut. Consumption of fermented kimchi was thus observed 
to have an effect in regulating the metabolic profile of human subjects.183 
1.4.3.  Sauerkraut  
A six-week, randomized, double-blinded study by Nielsen and colleagues204 investigated the 
effects of daily lacto-fermented sauerkraut on IBS symptoms of 34 Norwegian patients (15 
consumed a pasteurized sauerkraut supplement and 19 consumed unpasteurized sauerkraut 
supplement). Gut microbiota composition was analyzed using 16S rRNA gene amplicon 
sequencing of fecal samples and IBS symptoms were assessed through the IBS-Symptom 
Severity Score (IBS-SSS) questionnaire. IBS symptoms significantly improved in both groups 
without significant differences between groups. Both groups also showed significant changes 
in gut microbiota composition with Lactobacillus plantarum and Lactobacillus brevis 
significantly elevated in the unpasteurized sauerkraut group. Due to significant improvements 
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in the measured outcomes of both groups, the authors highlight the potential effects of the 
prebiotics rather than lactic acid bacteria.204 
Several lactic acid bacteria strains possess conjugated linoleic acid (CLA)-producing 
ability.205 CLA has demonstrated positive influences on gut microbiota in addition to efficacy 
against cancer, obesity, atherosclerosis, and diabetes.193,206 Lactic acid bacteria found in 
sauerkraut has proven effective in the reduction of pouchitis in patients with UC. Mechanisms 
of action of these probiotics might be through the interaction of these microorganisms with 
regulatory T cells and cytokine transcription factor regulation in response to disease-causing 
bacteria.207 Specifically, Lactobacillus acidophilus found in sauerkraut was observed to reduce 
the activation of the NF-B signaling pathway leading to a reduction of IL-8 and TNF- in the 
lamina propria mononuclear cells; thus reducing inflammation in individuals with ulcerative 
colitis.208 Moreover, sauerkraut reduced the incidence of diarrhea in patients receiving pelvic 
irradiation and prevented urogenital infections caused by E. coli and other bacterial pathogens 
related to the presence of Lactobacillus acidophilus.209  
1.5.  Significance of the Problem 
“Chronic diseases are the leading causes of death and disability worldwide.”210 As of 2016, 
more than 1.9 billion adults and over 340 million children and adolescents worldwide were 
classified as overweight or obese.211 The prevalence of obesity in America has increased from 
30.5% in 1999-2000 to 42.4% in 2017-2018.212 In 2008, the estimated annual medical cost of 
obesity was $147 billion, or $1,429 higher than those of normal weight.213 By 2010, obesity-
related medical care costs totaled $315.8 billion or $3,508 per obese individual among US 
adults.214 The US diabetes prevalence is projected to increase from 9.3% in 2012 to 33% by 
2050215 with related medical costs of approximately $245 billion per year.216 In 2018, the 
prevalence of diabetes in the US was about 34.2 million Americans with approximately 
210,000 of those under the age of 20.217 CVD is the leading cause of death in the US, and by 
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2030, 40.5% of the US population is projected to have some form of CVD with an according 
increase of direct medical cost from $273 billion in 2010 to $818 billion in 2030.218 In the past 
decade, IBD has become a major public health challenge with an estimated annual rise of 0.3% 
worldwide.143,144 In North America and Europe alone, approximately three million adults suffer 
from IBD.219  
 Consumption of fermented foods might be a realistic strategy to decrease chronic 
disease. While fermented food consumption in the US is rising, a more consistent intake is 
needed to improve gut health and reduce disease. In addition to increasing kimchi consumption, 
experts suggest that Americans substitute fermented pickles and fermented sauerkraut for non-
fermented pickles and cabbage as strategies to improve fermented food intake.220,221  
1.6.  Problem Statement  
There exists a high prevalence of dysbiosis-related diseases worldwide that are correlated to 
poor dietary habits.19,83,172,222 Several strategies have been proposed to tackle the accumulating 
disease rates. Till date, strategies used to treat these underlying conditions involve the use of 
surgery (inflammatory bowel diseases and obesity), insulin (to lower blood glucose levels), 
dietary changes and exercise, and medication.223–226 There is limited evidence of the effect of 
consuming fermented vegetables on changes in the gut microbiome and disease.173,182,227,228 
Feeding trials are needed to determine whether consumption of fermented vegetables is an 
effective strategy to prevent and treat disorders associated with inflammation. Consuming 
fermented vegetables for the prevention and treatment of disease might prove to be a least 
expensive option. 
1.7.  Research Questions and Hypothesis  




1. What is the impact of regular consumption of fermented vegetables for six weeks 
on metabolic markers of adult women? 
2. What is the impact of regular consumption of fermented vegetables for six weeks 
on the intestinal microbiome of adult women? 
1.7.2.  Study aims and hypothesis 
Study aim 1: To examine the effects of regular consumption of fermented vegetables for six 
weeks on markers of metabolic syndrome and inflammation in women. 
Hypothesis 1: Regular consumption of 100 g of fermented vegetables for six weeks will 
improve obesity-related markers such as blood pressure, insulin, adiposity, and inflammatory 
markers such as C-reactive protein and lipopolysaccharide in women. 
Study aim 2: To examine the effects of regular consumption of fermented vegetables for six 
weeks on the profile of the gut microflora 
Hypothesis 2: Regular consumption of 100 g of fermented vegetables will lead to a shift in 
microbial communities towards an increase in communities associated with health benefits, 













Chapter Two: Methods 
2.  Study Design  
This was a six-week, parallel arm, pilot and feasibility trial aimed at testing the effects of 
regular consumption of fermented vegetables on inflammation and the composition of the gut 
bacteria in women (clinical trial registration: NTC03407794). Participants were randomly 
assigned to one of three treatment groups: Group A (fermented vegetable group), Group B 
(non-fermented vegetable group), or Group C (control group). Over the course of six weeks, 
participants in the vegetable groups were asked to consume 100 g of vegetables per day in 
addition to following their regular diet. All vegetables were provided by the study. Group C 
was asked to follow their regular diet. Feces, urine, and blood samples were collected at two 
time points, baseline prior to randomization and at completion of the intervention. Group B 
served as a positive control, as subjects randomized into this group were instructed to 
consume the same vegetables as Group A, but without the presence of live bacteria.  
 All fermented vegetables were provided weekly by a local producer. All non-
fermented vegetables were obtained at a local grocery store. The non-fermented vegetables 
were comprised of shelf-stable pickles and sauerkraut. The study staff portioned out the 
vegetables using food safety precautions and delivered the vegetables to participants every 
two weeks. The microbial compositions of all four vegetable types; fermented sauerkraut, 
fermented pickles, non-fermented sauerkraut, and non-fermented pickles are shown in 
supplementary Figures S1-S5.  
2.1.  Study Participants   
Due to funding specifications, this pilot study aimed at recruiting 35 to 40 female 
participants. Inclusion criteria were: 
• Non-smoker 
• No previous diagnosis of cancer 
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• No thyroid disease 
• No diabetes 
• Willing to consume one half cup of vegetables per day for six weeks 
• Not on weight loss medication 
• Not on a weight loss diet 
• Not taking antibiotics over the past three months 
• Not consuming fermented vegetables on a regular basis 
• No history of autoimmune disease, including gastrointestinal disease 
• Those aged 18-70 years 
• No history of a psychiatric disorder 
• A signed informed consent  
Exclusion criteria: 
• Smoker 
• Taking medications that affect appetite or body weight 
• Uncontrolled hypertension 
• Not willing to consume one half cup of vegetables daily for six weeks 
• Not willing to show up at two appointments 
• Following a fad diet 
• Using antibiotics frequently 
• Diagnosed with autoimmune disease such as psoriasis, rheumatoid arthritis, thyroid 
disease, and colitis 
• Regular consumption of fermented vegetables or probiotics 
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• Having diminished capacity to consent (i.e. limited decision-making capacity, 
difficulty hearing, cognitive impairment that may impact understanding or 
compliance with nutritional counseling) 
• Non-English speaking or other language barrier 
• Having chronic kidney disease 
• Having any form of cancer that impacts nutritional status or undergoing radiation or 
chemo 
• Being treated for a psychiatric disorder or taking monoamine oxidase inhibitors  
• Not willing to provide informed consent 
This project was approved by the University of North Florida Institutional Review Board 
(IRB) and all participants provided informed consent prior to starting the study. 
2.2.  Study Procedures  
2.2.1.  Recruitment 
This study recruited only women due to their high accessibility and desire to limit significant 
variability of sex among participants. Flyers were posted at the UNF Women’s Center and 
Jacksonville Women’s clinics, and newspaper advertisements were also used to recruit 
participants. In addition, a recruitment email was sent to a random sample of females 
affiliated with the University of North Florida. Willing participants were instructed to contact 
the staff via phone or email using the contact information provided in the recruitment 
material. Once contacted by a potential participant, the study staff performed a screening 
interview to further confirm eligibility criteria. The flow of participants through the study is 
shown in Figure 1.   
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Figure 1. Flow of participants 
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2.3.  Study Visits 
Those who were eligible completed an in-person orientation session where the study 
procedures were explained in detail. At the orientation session, the consent form was 
reviewed and a baseline clinic visit was scheduled for those who signed the consent form. All 
participants who scheduled a baseline clinic visit at the orientation sessions received a urine 
and stool collection kit. Participants were instructed to collect a stool sample within 24 hours 
of their baseline clinic visit and the first-morning urine on the day of the baseline clinic visit. 
Coolers and ice packs were provided to help participants maintain the urine and stool samples 
cold until the morning of the clinic visit. At the baseline clinic visit, participants provided 
their urine, stool, and blood samples, and randomization into one of the three groups took 
place. Those randomized into one of the vegetable groups, made arrangements for the pick-
up and delivery of the vegetables. Similarly, prior to the follow-up clinic visit, participants 
were provided with more supplies to collect urine and stool samples.  
2.4.  Processing of biological samples 
Once received at clinic visits, all biological samples were stored at -70C until analysis. Blood 
was collected in two 8-mL red top tubes and left at room temperature for 30 minutes before 
centrifugation at room temperature for 10 minutes at 1400 rpm. Both serum and urine were 
transferred to 1.5 mL cryogenic tubes in 1-mL aliquots. Stool samples were transferred to 1.0 
mL cryogenic tubes in 150 mg-aliquots.  
2.5.  Data Collection  
2.5.1.  Surveys 
Participants completed online surveys to assess food intake, demographics, and prescription 
medication intake. The DHQ-3,229 a 135-item food frequency questionnaire designed by the 
National Cancer Institute, was used to assess the participant’s diet intake at baseline and 
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follow-up. As shown in Figure S6, participants were given a log to record their daily 
vegetable intake, gastrointestinal function (frequency of defecation and consistency of 
stools), and side effects (bloating, diarrhea, constipation, and headache). 
2.5.2.  Compliance 
Participants reported daily intake of vegetables by filling out a log sheet (see Figure S6). 
2.5.3.  Clinical Data 
Study staff members obtained participants’ height, weight, and body composition at each 
clinic visit. A Detecto 439 Eye Level Beam Physician Scale 400ib x 4oz with Height Rod 
was used to measure height in centimeters to the nearest 0.1 cm. Weight and percent body fat 
were measured by multifrequency bioelectrical impedance (InBody 570, Cerritos, CA.) 
Blood pressure was measured twice by a nurse using a sphygmomanometer.  
2.6.  Measurement of Biomarkers  
C-Reactive Protein (CRP) and Tumor Necrosis Factor (TNF) alpha were measured by 
commercial ELISA kits (Cat#DCRP00 for CRP and Cat#DTA00D for TNF alpha, R&D 
Systems, Minneapolis, MN). Lipopolysaccharide Binding Protein (LBP) was measured by a 
Pierce LAL chromogenic endotoxin quantitation kit (Cat#88282, ThermoFisher Scientific, 
Waltham, MA) and a sandwich enzyme immunoassay (catalog# DINS00, R&D Systems, 
Minneapolis, MN) was used to measure insulin levels. All analyses were conducted in the 
laboratory of Dr. Arikawa at the University of North Florida.  
2.7. Microbial Data Analysis  
DNA was extracted from the frozen stool samples with the DNeasy PowerLyzer PowerSoil 
Kit (Qiagen, Germantown, MD, USA) per manufacturer’s protocol. A NanoDrop One 
(Thermo Fisher Scientific, Madison, WI, USA) was used to measure DNA concentration and 
diluted to 10 ng/μL. DNA extraction and next-generation sequencing of the V4 region of the 
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16S rRNA gene were performed. Amplicon PCR was performed on the V4 region of 16S 
rRNA using the forward (5′-GTGCCAGCMGCCGCGGTAA-3′) and reverse (5′-
GGACTACHVGGGTWTCTAAT-3′) primers. PCR (polymerase chain reaction) amplicons 
were barcoded and pooled in equal concentrations using the SequalPrep Normalization Plate 
Kit (Invitrogen, Carlsbad, CA, USA). qPCR (quantitative PCR) was used to quantify 
consolidate libraries using the Kappa Library Quantification Kit (Roche, Indianapolis, IN, 
USA), and the quality of the library was determined by an Agilent 2100 Bioanalyzer 
(Agilent, Santa Clara, CA, USA). Sequencing was performed in a pair-end modality on the 
Illumina MiSeq 500 platform rendering 2 x 150 bp paired-end sequences (Illumina, San 
Diego, CA, USA)). Sequencing reads were analyzed using mothur v1.39.1230 following the 
MiSeq SOP, including steps for quality-filtering, alignment against a 16S reference database 
(SILVA v132), and clustering into operational taxonomic units (OTUs) with a pairwise 97% 
identity threshold. The OTUs were then classified using the Ribosomal Database Project 
database.231 Mothur v1.39.1. was used to calculate alpha diversity (microbial diversity within 
each sample) and beta diversity (microbial diversity between samples).232 For alpha diversity, 
we used observed operational taxonomic units (OTUs) to measure microbial richness 
(number of species present),233 Chao1 to measure species abundance,234,235, and the Shannon 
index to measure species richness and evenness (distribution).236,237 Three indices were also 
used to measure beta diversity. A principal component analysis (PCoA) was used to discover 
the percent of variability and potential associations among the groups represented by the 
Bray-Curtis (measure of differences in taxa abundance between communities) and Jaccard 
index (taxa presence/absence). Associations were computed between frequencies of the 
components and the two PCoA axes. An analysis of similarity (ANOSIM) was used to 
evaluate whether gut microbiota and diet composition were significantly different among the 
groups.34 Third, linear discriminant analysis (LDA) effect size (LEfSe) was used to identify 
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specific bacterial features that were enriched between conditions and diet patterns in each 
group or subgroup at the OTU level.34 All microbial analyses were conducted in the 
laboratory of Dr. Jiangchao Zhao from the Department of Animal Science at the University 
of Arkansas.  
2.8. Statistical Data Analysis  
The primary goal of the data analysis was to assess the feasibility of the study and obtain data 
on variability of the measures for the design of future adequately-powered studies. Given that 
there are no studies conducted in the United States that have investigated the effects of 
fermented vegetables on the gut bacteria and inflammatory markers, this study employed 
basic statistical tests for comparisons between groups and within group. Wilcoxon tests were 
used to compare pre- and post-data within the treatment groups for all study outcomes. 
Pearson’s correlation coefficients were calculated between all outcomes and alterations in the 
intestinal microflora. The Kruskal-Wallis test was used to compare medians across the three 
treatment groups at baseline, follow-up, and change (treatment effect). Change was 
calculated by subtracting follow-up data from baseline data.  
All analyses were performed using IBM SPSS (Statistical Package for the Social 








Chapter Three: Results 
3.1.  Characteristics of Study Participants 
Out of the 205 women who showed interest in the study, 34 were randomized into either Group 
A (fermented vegetable), Group B (non-fermented vegetable), or Group C (control), and 31 
participants completed the study. Participants’ ages ranged from 18 to 69 years, weights ranged 
from 47.5 kg to 114.1 kg, and BMIs ranged from 18.5 to 42.3 kg/m2. Participant’s baseline 
characteristics by treatment group are shown in Table 3.  
Table 3. Baseline characteristics of study participants 









37 (19-63) 44 (18-69) 27.5 (21-50) .575 
BMI (kg/m2) 
     
23 (19-44) 26 (18-37) 23 (21-34) .352 
Race (number, %)     
     White 8 (80) 9 (81.8) 6 (60) .477 
     Black 1 (10) 1 (9.1) 1 (10)  
     Asian 0 (0) 0 (0) 1 (10)  
     More than 1 
  
1 (10) 1 (9.1) 2 (20)  
Ethnicity (number, %)     
     Non-Hispanic 8 (80) 9 (81.8) 8 (80) .978 
     Hispanic 1 (10) 2 (18.2) 2 (2)  
     Did not disclose 
     
1 (10) 0 (0) 0 (0)  
Education (number, %)     
     Some college 2 (20) 2 (18.2) 2 (20) .775 
     College degree 3 (30) 4 (36.4) 5 (50)  
     Graduate degree 
     
5 (50) 5 (45.4) 3 (30)  
aData are medians (min-max) or number (%).  
bP-values represent between group comparisons among all three treatment groups using the 
Kruskal-Wallis test. 
Group A (fermented vegetable group), Group B (non-fermented vegetable group), Group C 






3.2.  Regular Dietary Intake of Participants 
Participant’s dietary characteristics were tracked throughout the study. Within and between 
group comparisons were made for timepoint 1, timepoint 2, and change values (Table 4). Group 
A showed a significant decrease (P=.043) in alcohol intake at the end of the study. Group C 
showed a 468 calorie decrease at timepoint 2 (P=.043) that was likely driven by the significant 
decrease in total protein intake from 72 g at timepoint 1 to 57 g at timepoint 2 (P=.043), along 
with a decrease in animal protein (P=.043), total fat (P=.043), cholesterol (P=.043), MUFA 
(P=.043), PUFA (P=.043), vegetable (P=.043), and vitamin E (P=.043) intakes. Between 
group comparisons show significant differences for animal protein (P=.009) and cholesterol 
(P=.015) intakes at timepoint 1, and cholesterol intake at timepoint 2 cholesterol (P=.023). 
Table 4. Dietary characteristicsa  
 
Variable Timepoint 1 Timepoint 2 Change P-valueb 
Energy (kcal/d)     
     Group A 
     Group B 
     Group C 




















Total Fat (g/d)     
     Group A 
     Group B 
     Group C 






















    
     Group A 168 (90) 181 (132) -4 (152) .678 
     Group B 
     Group C 












Total Protein (g/d)         
     Group A 49 (27) 43 (51) 10 (23) .260 
     Group B 51 (70) 60 (46) -10 (31) .398 
     Group C 72 (22) 57 (14) -20 (20) .043 
     P-valuec  .085 .849 .068  
Animal Protein 
(g/d)     
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     Group A 23 (11) 31 (32) 2 (23) .314 
     Group B 32 (13) 39 (39) -3 (34) .866 
     Group C 








Cholesterol (mg/d)         
     Group A 108 (125) 133 (156) 25 (66) .066 
     Group B 152 (202) 253 (272) 30 (189) .612 
     Group C 








Total SFA (g/d)     
     Group A 
     Group B 
     Group C 




















Total MUFA (g/d)     
     Group A 
     Group B 
     Group C 
     P-valuec 
 


















Total PUFA (g/d)     
     Group A 
     Group B 
     Group C 




















Starch Intake (g/d)     
     Group A 
     Group B 
     Group C 




















Fiber Intake (g/d)     
     Group A 
     Group B 
     Group C 




















Sugar Intake (g/d)     
     Group A 
     Group B 
     Group C 





















(total/d)     
     Group A 



















     Group C 









(g/d)     
     Group A 
     Group B 
     Group C 

























(cups/d)     
     Group A 
     Group B 
     Group C 
























Vitamin A Activity 
(RE/d)     
     Group A 
     Group B 
     Group C 
























Vitamin E Intake 
(IU/d)     
     Group A 
     Group B 
     Group C 
























Vitamin C Intake 
(mg/d) 
     Group A 
     Group B 
     Group C 
























HEI 2015 Score 
(total/d) 
     Group A 
     Group B 
     Group C 
























aValues are reported as median (IQR).  
bP-values represent within group comparisons between timepoint 1 and timepoint 2 obtained 
using the Wilcoxon Signed Ranks Test. 
cP-values represent between group comparisons among all three groups for timepoint 1, 
timepoint 2, and change obtained using the Kruskal-Wallis test. 
37 
 
Group A (fermented vegetable group), Group B (non-fermented vegetable group), Group C 
(control group), SFA (saturated fatty acid), MUFA (monounsaturated fatty acid), PUFA 
(polyunsaturated fatty acid), HEI (healthy eating index) 
3.3.  Vegetable Consumption of Study Participants 
Group A consumed an average of 91 g/d for 32 days (82% compliance) and Group B consumed 
an average of 91 g/d for 36 days (87% compliance).  
3.3.1. Side Effects of Vegetable Consumption 
 
Percent of participants who reported side effects:  
• Group A (fermented vegetable): 22.4% 
• Group B (non-fermented vegetable): 32.8% 
• Group C (control): 17.5% 
3.4.  Metabolic Biomarkers 
Participants’ clinical parameters are shown in Table 5. Significant changes between groups 
were found for body fat mass (BFM) (P=.048) and percent body fat PBF (P=.015). Group C 




Table 5. Clinical parameter changes after six weeks of intervention 
Clinical 
parametera 
Group A (n=11) Group B (n=10) Group C 
(n=10) 
P-valueb 
BMI (kg/m2)     
     Timepoint 1 
     Timepoint 2 

















     P-valuec 0.058 0.964 0.443   
BFM (kg)         
     Timepoint 1  18.8 (19.3) 26.2 (10.4) 18.0 (11.3) .493 
   Timepoint 2 20.0 (17.7) 27.4 (9.1) 17.3 (10.0) .239 
     Change  1.0 (2.0) -0.02 (1.8) -0.6 (1.0) .024 
     P-valuec 0.131 0.894 0.008   
PBF (%)           
     Timepoint 1 30.4 (22.6) 36.7 (5.6) 32.4 (12.8) .769 
     Timepoint 2 









     P-valuec 0.247 0.859 0.011   
DBP (mmHg)          
     Timepoint 1  81.0 (14.0) 75.5 (16.0) 75.0 (16.0) .599 
     Timepoint 2 









    P-valuec 0.476 0.389 0.374   
SBP (mmHg)     
     Timepoint 1 
     Timepoint 2 

















     P-valuec 0.858 0.866 0.037   
TNF (pg/mL)     
     Timepoint 1 
     Timepoint 2 

















     P-valuec 0.314 0.374 0.575   
CRP (ng/mL)     
     Timepoint 1 
     Timepoint 2 

















     P-valuec 0.214 0.086 0.139   
LBP (µg/mL)     
     Timepoint 1 
     Timepoint 2 

















     P-valuec 0.508 0.066 0.721   
aData are shown as median (IQR) or number (%). 
bP-values represent within group comparisons using the Wilcoxon Singed Rank test. 




TNF (tumor necrosis factor), CRP (C-reactive protein), BMI (body mass index), Wt (weight), 
BFM (body fat mass), LBF (lean body mass), PBF (percent body fat), DBP (diastolic blood 
pressure), SBP (systolic blood pressure), LBP (lipopolysaccharide binding protein) 
Group A (fermented vegetable group), Group B (non-fermented vegetable group), Group C 
(control group), TP1 (timepoint 1), TP2 (timepoint 2), TNF (tumor necrosis factor), CRP (C-
reactive protein), BMI (body mass index), Wt (weight), BFM (body fat mass), LBF (lean 
body mass), PBF (percent body fat), DBP (diastolic blood pressure), SBP (systolic blood 
pressure), LBP (lipopolysaccharide binding protein) 
 
3.5.  Alpha Diversity  
Microbial alpha diversity (within sample) can be analyzed on all taxa levels from phyla to 
subspecies and can be compared across groups. Although more indices exist, alpha diversity is 
typically measured using three indices; richness (number of species present such as observed 
OTUs233), species abundance (concentrations of the same species such as the Shannon236,237 
and Chao1 index234,235), and evenness (distribution of species such as the Shannon 
index236,237).34,238 Alpha diversity measures such as taxa abundance and taxa level, have 
correlated specific bacteria to disease phenotypes.239,240   
3.5.1.  Alpha Diversity of Vegetables 
Alpha diversity of the fermented and non-fermented vegetables is represented via taxa 
abundance, Shannon index, and observed OTUs as shown in Figures S1-S5. Figure S1 shows 
Firmicutes as the predominant phyla. Figure S2 shows Bacillales as the main genus. As 
represented by the Shannon index in Figure S3 and the observed OTUs in Figure S4, the non-
fermented sauerkraut contained the most alpha diversity among the four diet groups (non-
fermented pickles, non-fermented sauerkraut, fermented pickles, and fermented sauerkraut). 
Lastly, Figure S5 ranks the top 20 observed OTUs per relative abundance.  
3.5.2.  Alpha Diversity of Stool 
Alpha diversity measures of participants’ stool samples were also computed for taxa 
abundance, Shannon index, and observed OTUs. Firmicutes, Actinobacteria, and Bacteroidetes 
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represented the three predominant phyla among group and individual abundances. When 
stratified by treatment group and timepoint, Firmicutes remained the predominant phyla across 
all treatment groups (Figure 2). No significant abundance differences were found for within or 
between group comparisons using the Wilcoxon signed-rank and Kruskal-Wallis test, 
respectively. When stratified per individual, Firmicutes was the main phylum among most 
participants, but not all participants as shown in Figure 3.  
 
Figure 2. Taxonomy of phyla ranked by relative abundance and stratified by treatment group  
Firmicutes’ shows the highest abundance range of 70%-78% among all groups.  
A1 and A2 (fermented vegetable group timepoint 1 and timepoint 2), B1 and B2 (non-
fermented vegetable group timepoint 1 and timepoint 2), and C1 and C2 (control group 




Figure 3. Taxonomy of phyla ranked by relative abundance stratified by participant. A1 and 
A2 (fermented vegetable group timepoint 1 and timepoint 2), B1 and B2 (non-fermented 
vegetable group timepoint 1 and timepoint 2), and C1 and C2 (control group timepoint 1 and 
timepoint 2) 
Relative abundance on the genus level shows Blautia as the predominant genus across 
treatment groups with a relative abundance of 17-24% (Figure 4). No significant differences 
were found for within group comparisons using the Wilcoxon signed-rank test. Between group 
comparisons (Kruskal-Wallis test) showed significant diversity for Pasteurellaceae (P=.045) 
and Antinomyces (P=.035) genera; however, due to their low overall abundances, these genera 
are not shown in Figure 4. When stratified by individuals, Blautia remained the predominant 




Figure 4. Genus taxonomy ranked by relative abundance stratified by group.  
A1 and A2 (fermented vegetable group timepoint 1 and timepoint 2), B1 and B2 (non-
fermented vegetable group timepoint 1 and timepoint 2), and C1 and C2 (control group 
timepoint 1 and timepoint 2) 
 
 
Figure 5. Genus and order taxonomy ranked by relative abundance stratified by participant.  
A1 and A2 (fermented vegetable group timepoint 1 and timepoint 2), B1 and B2 (non-
fermented vegetable group timepoint 1 and timepoint 2), and C1 and C2 (control group 




Figure 6 shows significant differences in the Shannon index (measure of species richness and 
evenness)238 between group C and A at timepoint 2 (P=.037). Also, there was a trend towards 
an increase in alpha diversity measured by the Shannon in Group A. The observed OTUs 
(measure of species richness)238 showed significant differences between groups A and C and 
between Group B and C for timepoint 1 (P=.012 and P=.031, respectively). These differences 
were no longer significant between Groups B and C, or between Groups A and C.   
 
            
Figure 6. The Shannon index and observed OTUs (operational taxonomic units) represented 
through box-and-whisker plots. The whiskers show minimum and maximum values, the box is 
the 25th-75th percentile, and the line within the box is the median. 
A1 and A2 (fermented vegetable group timepoint 1 and timepoint 2), B1 and B2 (non-
fermented vegetable group timepoint 1 and timepoint 2), C1 and C2 (control group timepoint 
1 and timepoint 2). 
 
Figure 7 ranks the 20 most abundant OTUs found in participants’ stool samples. The top 
OTUs on the species level for each treatment group follow; Group A timepoint 1 Prevotella 
copri and Collinsella aerofaciens; Group A timepoint 2 Faecalibacterium prausnitzii and 
Blautia lut; Group B timepoint 1 Blautia wexlerae and Bifidobacterium longum; Group B 
timepoint 2 Blautia wexlerae and Bifidobacterium longum; Group C timepoint 1 Blautia 
wexlerae and Roseburia faecis; and Group C timepoint 2 Blautia wexlerae, and Roseburia 
faecis. We found significant between group difference for OTU 17 (Gemmiger formicilis). 
Faecalibacterium prausnitzii was significantly (P=.022) enriched in Group A at timepoint 2. 
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Moreover, as shown in Table 6, the alpha diversity results for Sobs (P=.014) and Chao1 
(P=.009) show significant differences for Group C (control group) at baseline.  
 
Figure 7. Top 20 OTUs (operational taxonomic units). OTUs are classified at the subgenus 
level and by relative abundance. The top 10 OTUs (species) follow; OTU 1 (Blautia wexlerae), 
OTU 2 Bifidobacterium (Bifidobacterium longum), OTU 3 Faecalibacterium 
(Faecalibacterium prausnitzii), OTU 4 Blautia (Blautia lut), OTU 5 Roseburia (Roseburia 
faecis), OTU 6 Blautia (Blautia glucerasea), OTU 7 (Akkermansia muciniphila), OTU 8 
(Collinsella aerofaciens), OTU 9 (Anaerostipes hadrus), OTU 10 (Ruminococcus bromii). 
A1 and A2 (fermented vegetable group timepoint 1 and timepoint 2), B1 and B2 (non-
fermented vegetable group timepoint 1 and timepoint 2), and C1 and C2 (control group 
timepoint 1 and timepoint 2) 
 
Table 6. Alpha Diversity between Groups 
Variablea Timepoint 1 Timepoint 2 Change P-
valueb 
Shannon Index     
     Group A 
     Group B 
     Group C 




















Sobs     















     Group B 
     Group C 








Chao1     
     Group A 109.35 (36.27) 108.12 (40.85) -7.67 (16.94) .059 
     Group B 
     Group C 












Table 6. Alpha diversity measures across the study.  
aValues are reported as median (IQR).  
bP-values represent within group comparisons between timepoint 1 and timepoint 2 
calculated via the Wilcoxon Signed Ranks Test. 
cP-values represent between group comparisons among group A, B, and C for timepoint 1, 
timepoint 2, and change values calculated via the Kruskal-Wallis test. Group A (fermented 
vegetable group), Group B (non-fermented vegetable group), Group C (control group), Sobs 
(observed subsample species richness)  
 
Correlations between alpha diversity, dietary intake, and clinical parameter values were 
computed for groups and individuals for timepoint 1, timepoint 2, and change values using 
Pearson’s correlations (Table 7). We found 13 medium (r=0.3-0.5, P<.05) correlations. The 
OTUs used in Table 7 reflect species level and were chosen because they demonstrated 




Table 7. Diet and clinical parameters correlated with alpha diversity measures 
 



















Energy  .361 (.011) .227 (.117) .190 (.191) .072 (.624) .219 (.130) -.037 (.802) -.230 (.111) -.020 (.893) 
Total Fat   .096 (.513) .102 (.487) .117 (.424) -.173 (.235) .138 (.343) .122 (.402) -.230 (.112) -.079 (.587) 
Total 
Carbohydrate 
.098 (.505) .140 (.338) .120 (.410) -.110 (.452) .145 (.321) .136 (.351) -.041 (.777) -.122 (.404) 
Total Protein  .169 (.245) .057 (.699) .062 (.671) -.073 (.618) .244 (.091) -.114 (.437) -.339 (.017) -.106 (.465) 
Animal Protein .214 (.140) .012 (.932) .001 (.992) .007 (.962) .123 (.399) -.271 (.060) -.339 (.017) .100 (.495) 
Cholesterol -.055 (.708) -.037 (.802) .051 (728) -.263 (.068) .031 (.831) -.162 (.266) -.361 (.011) -.073 (.617) 
SFA  .254 (.078) .170 (.242) .171 (.241) -.032 (.825) .057 (.700) -.078 (.594) -.321 (.025) .061 (.678) 
MUFA .109 (.455) .039 (.792) .040 (.783) -.106 (.470) .171 (.241) .118 (.420) -.275 (.056) -.016 (.912) 
PUFA .265 (.066) .096 (.511) .054 (.711) .309 (.031) .036 (.807) -.171 (.240) -.004 (.977) .080 (.587) 
Starch Intake .276 (.055) .214 (.140) .166 (.255) -.047 (.749) .192 (.187) .106 (.467) -.197 (.174) -.093 (.524) 
Fiber Intake .163 (.264) .162 (.265) .150 (.304) -.009 (.951) .138 (.343) .077 (.597) -.069 (.637) -.089 (.544) 
Sugar Intake .219 (.130) .282 (.045) .257 (.075) .078 (.594) .162 (.266) -.048 (.744) .133 (.362) -.028 (.851) 
Glycemic Load .291 (.042) .260 (.072) .218 (.132) .109 (.457) .186 (.201) .087 (.551) .029 (.841) -.022 (.882) 
Alcohol Intake .109 (.457) .035 (.810) .014 (.926) -.173 (.235) -.016 (.911) .067 (.649) -.202 (.164) .162 (.268) 
Vegetable 
Intake 
.202 (.165) .165 (.257) .148 (.311) .092 (.527) .140 (.338) .048 (.744) -.181 (.214) .310 (.030) 
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Yogurt  .255 (.077) .299 (.037) .329 (.021) -.125 (.392) .035 (.812) -.261 (.070) -.137 (.348) -.034 (.815) 
Vitamin B1 .305 (.033) .105 (.471) .080 (.587) .185 (.203) .328 (.021) .014 (.927) -.240 (.096) -.126 (.389) 
Vitamin B2 .203 (.161) .210 (.147) .216 (.135) -.046 (.752) .027 (.854) .060 (.680) -.201 (.166) -.092 (.528) 
Vitamin B12 .060 (.683) .093 (.523) .122 (.404) -.092 (.529) .058 (.692) -.007 (.964) -.191 (.188) -.152 (.297) 
Vitamin A 
Activity  
.221 (.128) .108 (.459) .115 (.432) .141 (.333) .135 (.356) .203 (.162) -.165 (.256) -.014 (.925) 
Vitamin E 
Intake 
.182 (.210) .007 (.964) -.025 (.866) .250 (.083) .271 (.060) .042 (.777) -.066 (.650) -.083 (.571) 
Vitamin C 
Intake 
.126 (.389) -.008 (.955) -.012 (.934) .324 (.023) .358 (.011) .071 (.629) -.065 (.657) -.005 (.972) 
HEI 2015 Score .263 (.068) .212 (.144) .111 (.447) .104 (.478) .046 (.753) -.110 (.453) .022 (.881) .078 (.593) 
Clinical Parameters 
Age .254 (.052) .265 (.042) .180 (.172) -.224 (.088) -.133 (.314) -.244 (.062) -.095 (.476) .226 (.085) 
Wt -.135 (.310) -.199 (.131) -.220 (.107) .109 (.409) .114 (.392) .166 (.209) -.080 (.546) .001 (.996) 
BMI -.176 (.181) -.175 (.186) -.192 (.145) .153 (.247) .115 (.385) .122 (.357) .075 (.572) .014 (.917) 
LBM  .047 (.726) -.075 (.574) -.149 (.261) .003 (.982) .056 (.672) .137 (.302) -.156 (.239) -.091 (.494)  
BFM -.194 (.140) -.221 (.093) -.212 (.107) .139 (.294) .118 (.372) .148 (.262) -.029 (.825) .043 (.744) 
PBF -.237 (.071) -.206 (.118) -.168 (.204) .130 (.327) .080 (.545) .134 (.313) -.010 (.938) .108 (.414) 
SBP .023 (.871) .047 (.738) .101 (.468) -.302 (.026) -.067 (.632) .138 (.319) -.125 (.367) .072 (.607) 
DBP .015 (.917) -.082 (.556) -.112 (.421) -.109 (.434) -.079 (.568) .087 (.534) -.010 (.938) .023 (.866) 
TNF .004 (,977) -.093 (.508) -.097 (.491) -.085 (.546) .200 (.152) -.055 (.694) -.078 (.577) .297 (.031) 
CRP -.033 (.813) -.182 (.191) -.235 (.090) .041 (.773) .121 (.388) -.089 (.525) .072 (.607) -.011 (.937) 
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LBP -.033 (.815) -.180 (.197) -.237 (.088) -.042 (.767) .199 (.153) .023 (.869) -.096 (.494) .132 (.346) 
 
Values are reported as Pearson’s coefficient (P-value). SFA (saturated fatty acid), MUFA (monounsaturated fatty acid), PUFA (polyunsaturated 
fatty acid), HEI (healthy eating index), Wt (weight), BMI (body mass index), LBM (lean body mass), BFM (body fat mass), PBF (percent body 
fat), SBP (systolic blood pressure), DBP (diastolic blood pressure), TNF (tumor necrosis factor), CRP (C-reactive protein), LBP 
(lipopolysaccharide binding protein) 
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Correlations between specific genera, dietary intake, and clinical parameter values were 
computed among groups and individuals for timepoint 1, timepoint 2, and change values 
using Pearson’s correlations (Table 8). We found one high (r>0.5, P<.05) and 14 medium 
(r=0.3-0.5, P<.05) correlations. The genera in Table 8 were chosen based on significant 






















Dietary Parameters          
Energy  -.058 (.694) .119 (.417) .098 (.501) .090 (.537) .214 (.140) .060 (.681) .209 (.150) -.065 (.657) -.226 (.119) .133 (.364) 
Total Fat   .043 (.769) .055 (.707) .138 (.343) .051 (.727) .139 (.341) -.220 (.129) .131 (.369) -.070 (.633) -.226 (.118) -.052 (.725) 
Total Carbohydrate -.031 (.830) -.064 (.661) .179 (.217) .081 (.581) .147 (.313) -.128 (.379) .052 (.723) -.122 (.403) -.040 (.787) -.094 (.519) 
Total Protein  .119 (.414) .002 (.988) .098 (.501) -.001 (.995) .236 (.102) -.105 (.475) .278 (.053) .046 (.754) -.332 (.020) .027 (.854) 
Animal Protein .146 (.317) .015 (.921) -.047 (.747) -.050 (.733) .105 (.472) .004 (.978) .126 (.389) .139 (.339) -.330 (.021) .266 (.065) 
Cholesterol .278 (.053) -.076 (.606) -.059 (.685) -.082 (.574) .019 (.895) -.285 (.047) .115 (.430) .169 (.247) -.345 (.015) .122 (.404) 
SFA  .113 (.438) .096 (.511) -.038 (.795) .063 (.668) .050 (.735) -.070 (.633) .068 (.641) .038 (.794) -.315 (.028) .291 (.042) 
MUFA .033 (.821) .078 (.594) .170 (.243) .058 (.691) .166 (.253) -.162 (.267) .112 (.445) -.052 (.723) -.274 (.057) .068 (.643) 
PUFA -.129 (.375) .129 (.376) -.076 (.606) .047 (.751) .031 (.833) .344 (.015) .046 (.756) .031 (.831) -.006 (.969) .223 (.123) 
Starch Intake -.067 (.647) .040 (.783) .182 (.211) .048 (.745) .192 (.187) -.080 (.587) .230 (.112) -.038 (.798) -.197 (.174) -.032 (.827) 
Fiber Intake -.070 (.635) -.004 (.976) .100 (.494) .050 (.734) .141 (.334) -.051 (.730) .303 (.035) -.052 (.724) -.066 (.654) -.151 (.301) 
Sugar Intake -.205 (.158) -.009 (.954) .155 (.289) .053 (.719) .166 (.256) .129 (.377) -.035 (.811) -.046 (.753) .137 (.346) -.062 (.670) 
Glycemic Load -.193 (.185) .003 (.984) .178 (.221) .067 (.646) .187 (.197) .141 (.334) -.028 (.847) -.103 (.482) .029 (.842) -.054 (.715) 
Alcohol Intake .059 (.689) .312 (.029) -.030 (.836) -.077 (.599) -.022 (.881) -.196 (.176) .163 (.264) -.167 (.250) -.208 (.152) -.035 (.814) 
Vegetable Intake -.010 (.947) .200 (.168) .054 (.715) .133 (.362) .145 (.319) .023 (.876) .214 (.140) -.126 (.389) -.176 (.226) -.001 (.993) 
Yogurt  .059 (.686) -.064 (.662) .251 (.082) -.141 (.333) .024 (.870) -.110 (.453) .124 (.396) .096 (.513) -.119 (.414) .191 (.188) 
Vitamin B1 -.035 (.804) -.011 (.939) .193 (.183) .170 (.243) .319 (.025) .181 (.214) .243 (.093) .003 (.985) -.244 (.091) .102 (.485) 
Vitamin B2 -.172 (.236) .155 (.289) .064 (.663) .429 (.002) .019 (.896) -.032 (.826) .067 (.646) -.033 (.822) -.201 (.166) .011 (.938) 
Vitamin B12 -.073 (.616) .122 (.404) .009 (.953) .398 (.005) .049 (.739) -.083 (.571) .107 (.464) -.087 (.553) -.192 (.185) .013 (.927) 
Vitamin A Activity  -.051 (.727) .239 (.098) -.005 (.974) .171 (.239) .137 (.348) .085 (.561) .192 (.185) -.230 (.112) -.170 (.242) .018 (.901) 
Vitamin E Intake -.122 (.402) -.038 (.796) .215 (.137) .205 (.158) .269 (.061) .213 (.142) .115 (431) -.110 (.451) -.069 (.637) .010 (.944) 
Vitamin C Intake -.091 (.533) -.011 (.941) .038 (.796) .189 (.194) .362 (.011) .299 (.037) .231 (.110) -.190 (.192) -.066 (.651) .006 (.965) 
HEI 2015 Score -.248 (.085) -.011 (.942) .152 (.297) .048 (.741) .044 (.764) .125 (.390) .117 (.423) .035 (.813) .020 (.893) .088 (.548) 
Clinical Parameters 
Age -.047 (.724) .055 (,680) .086 (.519) -.389 (.002) -.138 (.298) -.176 (.183) -.171 (.196) .532 (.000) -.095 (.475) .085 (.524) 
Wt -.202 (.124) -.105 (.453) -.296 (.023) .296 (.023) .115 (.387) .124 (.350) .157 (.236) .055 (.680) -.101 (.447) -.011 (.933) 
BMI -.278 (.033) .050 (.708) -.241 (.066) .274 (.036) .123 (.352) .158 (.233) .069 (.605) .007 (.958) .054 (.684) -.072 (.587) 
LBM  -.143 (.281) .095 (.475) -.290 (.026) .277 (.034) .047 (.726) .046 (.727) .351 (.006) .116 (.380) -.164 (.215) .119 (.371) 
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BFM -.193 (.142) .056 (.673) -.241 (.066) .250 (.056) .124 (.378) .138 (.299) .033 (.806) .013 (.920) -.052 (.698) -.073 (.584) 
PBF -.132 (.318) .005 (.967) -.170 (.198) .197 (.135) .090 (.499) .109 (.409) -.063 (.633) -.032 (.810) -.039 (.772) -.109 (.410) 
SBP -.056 (.634) .138 (.321) -.204 (.138) .077 (.578) -.073 (.601) -.235 (.087) .111 (.423) -.071 (.609) -.127 (.361) -.231 (.092) 
DBP -.055 (.691) -.021 (.882) -.214 (.120) .031 (.824) -.087 (.532) -.065 (.642) .152 (.273) .089 (.521) -.059 (.671) .252 (.066) 
TNF -.092 (.511) -.105 (.453) .117 (.404) .156 (.266) .192 (.169) -.042 (.768) -.275 (.046) .020 (.888) -.082 (.558) -.227 (.103) 
CRP .061 (.665) -.121 (.389) .230 (.098) -.076 (.587) .124 (.378) .028 (.840) -.078 (.579) .071 (.612) .053 (.706) -.119 (.396) 
LBP .091 (.517) .039 (.782) -.163 (.245) .102 (.468) .198 (.155) -.075 (.592) .142 (.311) -.054 (.703) -.116 (.408) .133 (.343) 
 
Values are reported as Pearson’s coefficient (P-value).  
SFA (saturated fatty acid), MUFA (monounsaturated fatty acid), PUFA (polyunsaturated fatty acid), HEI (healthy eating index), Wt (weight), 
BMI (body mass index), LBM (lean body mass), BFM (body fat mass), PBF (percent body fat), SBP (systolic blood pressure), DBP (diastolic 





3.6. Beta Diversity 
Beta diversity compares diversity between samples by calculating microbial dissimilarity that 
is shown in a distance matrix such as the Bray-Curtis and Jaccard index.241 The Bray-Curtis 
is a quantitative measure of taxa abundance,232 while the Jaccard distance is a qualitative 
measurement that represents feature presence/absence rather than relative abundances.242 In  
terms of beta diversity (between samples), no significant within group plot variations or 
patterns were found for longitudinal comparisons of PCoA plots for Bray-Curtis (Figure 9) or 
Jaccard (Figure 10) distances. 
Figure 9. PCoA plots showing Bray-Curtis distances for within group (Group A, B, and C), 
longitudinal (timepoint 1 to timepoint 2) measures. (A) fermented vegetable group, (B) non-
fermented vegetable group, (C) control group    
 
Figure 10. PCoA plots showing Jaccard distances for within group (Group A, B, and C), 
longitudinal (timepoint 1 to timepoint 2) measures. (A) fermented vegetable group, (B) non-
fermented vegetable group, (C) control group    
 
Further microbial analysis used ANOSIM based on Bray-Curtis and Jaccard distances to 
compared beta diversity within and between all groups (Groups A, B, and C) and timepoints 
                   
                                                                                  
C B A 
A B C 
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(timepoint 1 and 2) (Figure 11). No strong dissimilarities were found for the Bray-Curtis or 
Jaccard distances.  
Figure 11. ANOSIM (analysis of similarity) via Bray-Curtis and Jaccard distances. A1 
fermented vegetable group at timepoint 1), A2 (fermented vegetable group at timepoint 2), 
B1 (non-fermented vegetable group at timepoint 1), B2 (non-fermented group at timepoint 2), 
C1 (control group at timepoint 1), C2 (control group at timepoint 2) 
Longitudinal LEfSe results identified several enriched OTUs. LDA scores greater than 2 are 
considered significant (P>0.05). The LEfSe results for Group A (fermented vegetable group) 
show OTU 32 (Ruminococcus torques) significantly more enriched at timepoint 1 than 
timepoint 2 as represented by a LDA score of 3.6 in Figure 12A, and a side-by-side comparison 





Figure 12. (A) Longitudinal linear discriminant analysis (LDA) effect size (LEfSe) for Group 
A (fermented vegetable group) at timepoint 2 (B) Relative abundance of OTU 32 
(Ruminococcus torques) stratified by study participant and timepoint (A1 = timepoint 1, 
A2=timepoint 2). 
 
The LEfSe results for Group B (non-fermented vegetable group) show OTU 206 
(Negativibacillus massiliensis) significantly more enriched at timepoint 2 than at timepoint 1 
as represented by a LDA score of 3.0 in Figure 13A, and a side-by-side comparison of relative 




Figure 13. (A) Longitudinal linear discriminant analysis (LDA) effect size (LEfSe) for Group 
B (non-fermented vegetable group) at timepoint 2 (B) Relative abundance of OTU 206 
(Negativibacillus massiliensis) stratified by study participant and timepoint (B1 = timepoint 1, 
B2 = timepoint 2). 
 
The LEfSe results for Group C (control group) show OTU 163 (Mediterraneibacter 
glycyrrhizinilyticus) significantly more enriched at timepoint 2 than at timepoint 1 as 
represented by a LDA score in Figure 14A, and a side-by-side comparison of relative 









Figure 14. (A) Longitudinal linear discriminant analysis (LDA) effect size (LEfSe) for 
Group C (control group) at timepoint 2 (B) Relative abundance of OTU 163 
(Mediterraneibacter glycyrrhizinilyticus) stratified by study participant and timepoint (C1 = 
timepoint 1, C2=timepoint 2). 
 
Some species within the same phylum, genus, and other taxa have various functions and 
benefits. There is tremendous diversity in the activities of bacteria. To highlight the various 
functions of species noted in this study, Table 9 lists the 10 most abundant species and four 
species with significant diversity measures along with their reported functions and benefits.   
Table 9: Reported function(s) and Association(s) of significant species 
OTU Subgenera Species Reported Function(s) and 
Association(s) 
1 Blautia Blautia wexlerae Intestinal immune homeostasis, glucose 
homeostasis, anti-obesogenic243 
2 Bifidobacterium Bifidobacterium 
longum 
Produces SCFAs, conjugated linoleic 
acid, and bacteriocins that protect 
against infection;244 decreased in CF, 
CD, and IBD; increased in diabetes245 
3 Faecalibacterium Faecalibacterium 
prausnitzii 
Butyrate-producing bacteria with anti-
inflammatory effects246–248 through 
blockage of the NF-κB pathway;249 
decreased in IBD250 with potential role 
as an IBD biomarker;249 decreased in 
CF, CD, hepatitis B cirrhosis, 
gastroenteritis; increased in obesity245 
4 Blautia Blautia luti Intestinal immune homeostasis, glucose 
homeostasis, anti-obesogenic;243 
decreased in graft-versus-host disease245 
5 Roseburia Roseburia faecis Decreased in IBD245 
6 Blautia Blautia glucerasea Decreased in Parkinson's disease245 
7 Akkermansia Akkermansia 
muciniphila 
Increased in gastrointestinal helminths 
infection, colorectal cancer; decreased in 
nonalcoholic liver disease, CD, UC, 
obesity245 
8 Collinsella Collinsella 
aerofaciens 
Decreased in CF, IBS, UC, CD; 
increased in metabolic syndrome, CAD, 
colorectal cancer251 
9 Anaerostipes Anaerostipes 
hadrus 
Decreased in primary sclerosing 
cholangitis, obesity, MS, CD, UC, CF251 
10 Ruminococcaceae Ruminococcus 
bromii 
Decreased in CD, increased in IBS245 
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12 Prevotella Prevotella copri Increased in peritoneal dialysis; 
decreased in Parkinson's disease245 
32 Ruminococcu2 Ruminococcus 
torques 
Increased in CD, UC, IBS245 
163 Lachnospiraceae Mediterraneibacter 
glycyrrhizinilyitcus 
No information found 
206 Ruminococcaceae Negativibacillus 
massiliensis 
No information found 
CAD (coronary artery disease), CD (Crohn’s disease), CF (cystic fibrosis), IBS (irritable 


















Chapter Four: Discussion and Conclusions 
4.  Discussion 
This parallel arm, pilot and feasibility study, explored the effects of fermented vegetable 
consumption for six weeks on markers of inflammation and gut microflora profiles of women. 
Findings included, a significant increase in Faecalibacterium prausnitzii among Group A 
(fermented vegetable group) at timepoint 2, an upward trend in Shannon index among Group 
A at timepoint 2, and 28 moderate to strong correlations between alpha diversity and dietary 
and clinical parameters.  
Most research on this topic has been conducted in Asian countries where fermented 
vegetables are widely consumed and in much larger quantities as compared to the typical 
consumption of fermented vegetables in the United States.184,194,200,227 We believe that this is 
the only study conducted in the United States that examined the effects of regular consumption 
of fermented vegetables for six weeks on markers of metabolic syndrome and inflammation, 
and gut microflora profiles in women. Moreover, these studies of Asian origin used kimchi as 
the main source of the fermented vegetables as compared to our study that used fermented 
sauerkraut and pickles that contain different bacteria strains and amounts. The lack of research 
on this topic, particularly in the United States, leaves a huge gap in the knowledge about the 
role of fermented vegetables in Western cultures. This study assessed the feasibility and the 
effects of regular consumption of fermented vegetables in a group of women living in Florida. 
The amount and duration of fermented vegetable consumption that our participants were asked 
to consume were selected based on what the researchers considered a realistic amount for our 
population to consume, given that fermented vegetables are not widely common in the Western 
diet.  
4.1. Vegetable Consumption 
58 
 
Vegetable intake compliance was similar between Group A and Group B, which helped 
contribute to a more accurate analyses of between group comparisons for outcomes measured; 
however, vegetable consumption is at risk for inaccuracies due to the nature of self-reported 
intakes. It appears that 100 g of vegetable consumption for 6 weeks was well-tolerated. The 
groups did well with vegetable compliance and tolerance, although some participants 
commented that compliance was difficult towards the end mainly due to the taste that 
fermentation gave the vegetables and redundancy of consuming the same vegetables. Bloating 
was the main side effect reported in Groups A and B with Group B reporting the most bloating. 
Bloating was expected due to the nature of sauerkraut being a cruciferous vegetable. 
Abdominal pain was the main side effect among Group C perhaps due to the placebo effect.  
4.2.  Measured Outcomes 
4.2.1.  Baseline Parameters 
Baseline characteristics such as age, BMI, race, ethnicity, and education were not significantly 
different between the three groups; thus, limiting bias contributions to study results.  
4.2.2. Dietary and Clinical Parameters 
Group A had a significant within group reduction for alcohol intake likely related to personal 
choices rather than fermented vegetable intake, and Group B did not show any significant 
within group changes. Even with the high sodium content of fermented vegetables due to the 
brine solution, no related, significant, increases in blood pressure were found as salt sensitivity 
does not occur in most people.252 Surprisingly, Group C demonstrated the most within group 
changes in dietary intake as represented by eight significant reductions; energy, total protein, 
animal protein, total fat, cholesterol, MUFA, PUFA, vegetable, and vitamin E. It is unclear 
why Group C displayed the most changes (reductions) from timepoint 1 to timepoint 2. The 
468 calorie decrease between timepoints in Group C was likely due to the total protein and 
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total fat intake reductions, which are further connected to the other reductions in cholesterol, 
MUFA, PUFA, vegetable, and vitamin E intakes. Group C’s overall intake dropped 
significantly more than Group A and B. In addition to a small sample size, intentional desire 
of some participants to improve dietary intake and/or physical activity level, or unintentional 
changes in dietary intake such as loss of appetite related to stress or sickness may have also 
played a factor. Inaccurate self-reporting on the FFQ is not a likely cause for changes in Group 
C’s dietary intake changes because the reductions in the group’s metabolic markers (BFM, 
PBF, weight, SBP) support the dietary changes. Group C demonstrated the significant 
reductions in BFM, PBF, weight, and SBP as compared to Groups A and B. None of the groups 
demonstrated significant changes in inflammatory markers (TNF, CRP, LBP). It was 
hypothesized that Group A would demonstrate at least one metabolic or inflammatory marker; 
however, this did not occur most likely due to the study’s small population size and insufficient 
probiotic/fermented vegetable intake. Standardized prebiotic and probiotic definitions are a 
major contributor to developmental research, but further research is needed to develop 
recommended dietary intakes and their according food labels that clearly show abundance 
measures to better know how much is needed to create desired change.133  
4.2.3.  Alpha Diversity 
4.2.3.1.  Vegetables  
Alpha diversity measures of the fermented and non-fermented vegetables showed higher 
diversity in the non-fermented vegetables compared with the fermented vegetables. However, 
the fermented sauerkraut and fermented pickles showed a greater enrichment of the genera 
Lactobacillus and Leuconostoc as compared to their non-fermented counterparts, which is in 
agreement with literature findings that report Lactobacillus and Leuconostoc are among the 
main bacteria in fermented sauerkraut and fermented pickles.186,190 Bacillales is the 
predominant order among the non-fermented sauerkraut and non-fermented pickles. Fresh 
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vegetables are known to harbor bacteria such as Bacillales253–255 at any time from the field to 
consumption.255,256 In addition to sauerkraut’s cruciferous benefits, the differences in diversity 
between the pickles and sauerkraut, likely contributed to participants’ microbial outcomes. 
4.2.3.2.  Fecal  
The fecal alpha diversity analysis did not show any significant differences in the RA for within 
or between group comparisons for any phyla, but there were significant between group 
differences for the family Pasteurellaceae and genera Antinomyces; however, due to their very 
low abundances, these genera were not reported in the figure. The main five phyla identified 
in stool samples were Firmicutes (RA 75%), Actinobacteria (RA 12%), Bacteroidetes (RA 
10%), Verrucomicrobia (RA 1.8%), and Proteobacteria (RA 0.5%). These results are similar 
to other research that report Firmicutes is typically the predominant phyla followed by 
Bacteroidetes followed by Actinobacteria, Proteobacteria, and Verrucomicrobia.11,257 King and 
colleagues258 created a healthy human gut microbiota profile model (GutFeelingKB) based on 
taxa RA that can be used as a healthy control for dysbiosis-related research, and a standardized 
Fecal Biome Population Report (FecalBiome) for reporting individual microbiota profiles. 
GutFeelingKB is a compilation of data collected from a “healthy” people cohort at George 
Washington University and “healthy” HMP subjects. The healthy people cohort participants 
were deemed "healthy" according to analysis (by the Nutrition Data System for Research) of 
their seven-day food journals and were free of disease throughout the study. Forty-eight stool 
samples from the healthy people cohort along with 50 stool samples from the healthy HMP 
subjects were ran through CensuScope, a taxonomic profiling software, that calculated 
abundance quantification. Those organisms with the highest abundance measures were then 
manually evaluated per four major criteria (inspection of the match count, confirmation of a 
justifiable taxonomy assignment, completeness of sequence in the GutFeelingKB, and 
organism verification) that resulted in 157 organisms (8 phyla, 18 classes, 23 orders, 38 
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families, 59 genera and 109 species) added to the GutFeelingKB database for genome mapping. 
If closely related proteomes are considered, then the list can be expanded to include 863 
organisms. Different than our results, the GutFeelingKB phylum profile suggests a 
composition with Bacteroidetes (RA 73.13 ± 22.16%) as the dominant phyla followed by 
Firmicutes (RA 22.2 ± 18.66%), Proteobacteria (RA 2.15 ± 10.39%), and Actinobacteria (RA 
1.82± 3%),258 which is in accordance with similar research that reports better health and dietary 
patterns are present when Bacteroidetes is the dominant phyla followed by Firmicutes.259,260 
Furthermore, this study showed that, on average, Firmicutes was 10.6 times greater than 
Bacteroidetes and Actinobacteria was 20 times greater than Proteobacteria, while the 
GutFeelingKB suggests with Bacteroidetes to be approximately 3.3 times the amount of 
Firmicutes, and Proteobacteria about 1.2 times the RA of Actinobacteria.258 The RA of 
Proteobacteria and Actinobacteria remain similar among research as phylum minorities; 
however, even though these phyla are considered minor, they play pivotal roles in gut microbial 
homeostasis through their metabolic and immune influence. More research is needed to 
decipher if and how much the Proteobacteria/Actinobacteria ratio is correlated with optimal 
health, and their optimal RA for use as disease biomarkers.11,76,257,258,260–262 
As shown in Figure 4, the top genus bacteria included some order and family taxa; thus, 
when referring to this study’s genus bacteria some order and family taxa are included. When 
averaged among all participants, our top ten genera (RA) were Blautia (21%), 
Ruminococcaceae (9.6%), Bacteroides (6.4%), Bifidobacterium (5.9%), Roseburia (5.1%), 
Faecalibacterium (4.9%), Clostridiales (4.9%), Lachnospiraceae (4.7%), Collinsella (4.5%), 
and Anaerostipes (3.7%). By combining 22 sequenced fecal metagenomes of individuals from 
four countries with previously published data sets and two published lager cohorts, Arumugam 
and colleagues8 reported the top ten genus bacteria found in the human gut are Bacteroides, 
Faecalibacterium, Bifidobacterium, Lachnospiraceae, Roseburia, Alistripes, Collinsella, 
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Blautia, Coprococcus, and Ruminococcus,10,263 This study’s findings matched seven of the top 
ten bacteria, but in a different order. The GutFeelingKB ranked the top genus (RA) are 
Bacteroides (65.6%), Lachnospiraceae (6.2%), Ruminococcus (4.1%), Faecalibacterium 
(3.5%), Alistripes (3%), Parabacteroides (2.3%), Clostridiales (2.1%), Escherichia (2%), 
Roseburia (1.8%), Bifidobacterium (1.7%), Blautia (1.5%), and Akkermansia (0.7%).258 This 
study’s results also matched seven top genera of the GutFeelingKB, but with different RA. 
Both the reported top genus10,263 and the GutFeelingKB genus258 show Bacteroides as the 
predominant genera rather than Blautia as found in this study. Genus abundance profiles show 
greater variability than phylum abundance profiles, which likely accounts for the variation 
shown here between common,264 recommended,258 and our genus profile results. Of note, a 
substantial number of bacteria were classified as “others” rather than a known taxa. Current 
technology limits taxonomic identification of new bacteria as well as highly polyphyletic and 
phylogenetic bacteria; thus, classifying them as “others”. Future advances in taxonomy looks 
promising for increased classification of bacteria.9  
 We found significant differences in alpha diversity between groups at baseline; 
therefore, rather than focusing on between group comparisons we mainly focused on within 
group comparisons. We did not find any significant changes for within group comparisons 
based on the Shannon index or the observed OTUs, but did find significant diversity differences 
for between group comparisons likely due to the significant diversity differences between 
groups at baseline; thus, making within group comparisons a more accurate representation of 
treatment effect for this study.  
Faecalibacterium prausnitzii was the predominant species among Group A at timepoint 
2, which could be related to fermented vegetable intake. Faecalibacterium prausnitzii is one 
of the most abundant gut bacterium involved in gut homeostasis264,265 and it has been described 
as the “gatekeeper of the gut.”266 Faecalibacterium prausnitzii is an anti-inflammatory 
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bacterium that improves intestinal barrier protection, insulin sensitivity, oxidative stress 
tolerance, and visceral sensitivity.266 Faecalibacterium prausnitzii is a butyrate-producers and 
IL-10 stimulator that can block the IL-1β-induced NF-κβ signaling pathway.267–269 Clemete et 
al270 reported that Faecalibacterium prausnitzii inhibits pathogenic bacteria and increases 
colonization of nonpathogenic bacteria in the human gut. Group B and C retained the same 
predominant species for each group from timepoint 1 to timepoint 2.  
4.2.3.3.  Correlations 
Among Pearson’s correlation-coefficients that measured alpha diversity indices (Shannon 
index, Sobs, Chao1, species, and genera) with dietary intake and clinical parameters, we found 
one high (r>0.5, P<.05) correlation and 27 medium (r=0.3-0.5, P<.05) correlations. The 
positive correlation between age and Lachnospiraceae (r=.532, P=.000) is consistent with 
previous research reporting that Lachnospiraceae increases from infancy to about 50 years old, 
then decreases in extreme aging.271 Lachnospiraceae has been correlated with disease 
prevention and progression due to the bacteria's high phylogenetical taxonomy with both pro- 
and anti-inflammatory contributions.272 We found a negative correlation between age and 
Bifidobacterium (r=-.389, P=.002), which is supported by much documentation that reports 
Bifidobacterium decreases with age,244  We found a positive correlation between Shannon 
index and energy (r=.361, P=.011); however, similar studies only found strong correlations 
between Shannon index and overall diet quality, rather than energy intake.273,274 Our correlation 
findings for Bifidobacterium and vitamin B2 (r=.429, P=.002) and B12 (r=.398, P=.005) are 
supported by much research regarding gut microbiota and vitamin intake.275–278 Many 
Bifidobacterium species can de novo synthesize and supply vitamins such as vitamin B2 
(riboflavin) and B12 (cobalamin) to the human body. This is important because like most 
vitamins, vitamins B2 and B12 cannot be synthesized by humans and must be obtained from 
other sources such as food or intestinal microbiota. Vitamin‐producing microorganisms 
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provide the host with an ongoing supply of micronutrients.40,279,280 Vitamins B2 and B12 are 
involved in many essential functions of the human body such as cell metabolism and 
respiration, amino acid synthesis, energy production, cognitive function, immune support, 
and/or red blood cell production. Deficiencies in these vitamins have caused developmental 
defects, impair cognitive function, immune dysfunction, and abnormal blood production. 
Historically, nutritional deficiencies have been treated with supplementation that have either 
reversed the deficiency or caused vitamin toxicity leading to immune dysfunction, cancer, and 
increased mortality.40,281,282 The correlations between vitamin B1 and Roseburia (r=.319, 
P=.025) and Roseburia faecis (r=.328, P=.021) are in line with research regarding Roseburia 
and thiamine biosynthesis.283 We found positive correlations between vitamin C and Roseburia 
(r=.362, P=.011) and Roseburia faecis (r=.358, P=.011). Research regarding correlations 
between vitamin C and Roseburia or Roseburia faecis is lacking. A supplementation study by 
Pharm and colleagues275 reported a slight but consistent increase in Roseburia abundance after 
vitamin C supplementation of 500 mg of ascorbic acid per day for four weeks among 12 
participants. In agreement with similar studies, our results show negative correlations between 
Prevotella and total protein (r=-.332, P=.020), animal protein (r=-.330, P=.021), cholesterol 
(r=-.345, P=.015), and SFA (r=-.315, P=.028), and negative correlations between Prevotella 
copri and total protein (r=-.339, P=.017), animal protein (r=-.339, P=.017), cholesterol (r=-
.361, P=.011), and SFA (r=-.321, P=.025). Prevotella strains are associated with a plant-based 
diet characterized by high fiber and low protein.284,285 Interestingly, it has been suggested that 
Prevotella is not only associated with beneficial effects, but it is also linked to chronic 
inflammatory conditions, such as arthritis.286,287 Future studies are required to further explore 
the role of Prevotella in health and disease. The genus Faecalibacterium and species 
Faecalibacterium prausnitzii were moderately correlated with PUFA intake (r=.344, P=.015) 
and (r=.309, P=.031), respectively. Faecalibacterium prausnitzii is a butyrate-producing 
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bacterium with anti-inflammatory effects246–248 that is well-known for its inverse relationship 
with IBD.250 In accordance with our results, research has demonstrated a correlation between 
Faecalibacterium prausnitzii and PUFA intake; however, results are inconsistent.288–290 
Mokkala et al291 demonstrated a significantly higher abundance of Faecalibacterium 
prausnitzii among pregnant women after supplementation with PUFAs. We found a correlation 
between Clostridiales and fiber intake (r=.303, P=.035), which is comparable to other gut 
microbiota research. Clostridiales taxa is reported as the most active microbial components in 
the gut of healthy adults through their role in colonic fermentation of dietary fiber to SCFAs.292–
295 Clostridiales play a vital role on butyrate modification that may prove to be an effective 
probiotic treatment for intestinal homeostasis.294,296 We found a correlation between 
Clostridiales and LBM (r=.351, P=.006). Several studies also reported a correlation between 
Clostridiales and obesity.63 Zhang et al297 compared the human gut microbiota of nine 
individuals who were evenly distributed to one of three groups; normal weight, morbidly obese, 
or post-gastric-bypass. Clostridium, the genus taxa under the order Clostridiales was 
proportionally reduced among the post-gastric bypass group as compared to the normal weight 
and morbidly obese groups. The authors hypothesized that due to the bypass of the upper small 
intestine, these local bacteria relocated to the large intestine; thus, modifying microbiota 
composition and related outcomes.297 In a Japanese study, researchers extracted DNA from the 
stool of 20 participants; 10 lean and 10 obese and used 16S rRNA sequencing to detect 
microflora. Results showed higher Clostridiales levels in the obese as compared to the lean 
participants.298  
4.2.3.4. Beta Diversity 
While there were no significant differences for within group beta diversity for Bray-Curtis and 
Jaccard PCoA distances, the ANOSIM showed a significant difference in the Jaccard results 
for A2-C2 and A1-C1. The significant difference in A2-C2 is likely influenced by the diversity 
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differences at baseline and possibly from Group A’s fermented vegetable intake. We found 
strong between group dissimilarities for the Jaccard distance based on ANOSIM. Due to high 
variations in microbial diversity between groups at baseline, it was more appropriate to focus 
on within group comparison rather than between group comparisons. Within group LEfSe 
results for Group A showed significant differences for Ruminococcus torques, which was 
significantly decreased at timepoint 2. Research suggests that Ruminococcus torques is 
correlated with increased inflammation. Research regarding Ruminococcus torques and 
fermented vegetable consumption is very limited.140,299–302 Meslier et al140 found 
Ruminococcus torques to be reduced after an 8-week intervention of a Mediterranean diet as 
compared to the control group. Due to findings that low microbial richness is found among 
those with metabolic disease such as IBD5,303–305 and obesity,306 Chatelier and colleagues305 
further compared microbial richness and metabolic disease and report Ruminococcus torques 
as a "potentially pro-inflammatory" species. Brahe and colleagues307 report findings that 
Ruminococcus torques is positively correlated with insulin resistance and labeled it as a 
metabolic marker in postmenopausal women with obesity. Lastly, Odenwald and colleagues308 
also found Ruminococcus torques to be positively associated with insulin resistance due to its 
adverse effects the gut barrier that contribute to metabolic endotoxemia. 
Overall, we did not find significant associations between fermented vegetable 
consumption and Bifidobacteria or Lactobacilli as hypothesized, but we did find an upward 
trend in the Shannon index and a significant increase in the anti-inflammatory bacteria, 
Faecalibacterium prausnitzii, among Group A at timepoint 2, which could be related to 
fermented vegetable intake. The lack of our findings is likely related to a small sample size, 
lack of comparable studies there conducted in America, comparisons of drastically different 
dietary patterns over geographical provenances, the use of fermented sauerkraut and fermented 
pickles rather than fermented kimchi, the significantly higher amounts of fermented vegetable 
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consumption. In an eight-week controlled clinical trial that compared 180 g per day of 
fermented kimchi consumption to 180 g per day of fresh kimchi consumption there was a 
significant increase in Bifidobacteria spp. among the fermented kimchi group.203 A six-week, 
randomized, double-blinded intervention was conducted with 34 Norwegian IBS patients 
(n=19 fermented sauerkraut, n=15 non-fermented sauerkraut) to compared the effects of 
fermentation on GI symptoms and microflora. After a six-week supplementation with either 75 
g per day fermented or fresh sauerkraut, there was a significant increase in Lactobacillus 
plantarum and Lactobacillus brevis among the fermented sauerkraut group as compared to 
fresh sauerkraut group.136  
Overall, we did not demonstrate significant correlations between fermented vegetable 
intake and metabolic markers, but we did find 28 significant correlations among microbiota 
and vitamin B levels, obesity, and age that is supported by comparable research. As compared 
to similar research, it is possible that we did not find any significant patterns between fermented 
vegetable intake and metabolic markers as compared to other studies, not only because of a 
small sample size, but also because most of the comparable studies originated from Korea and 
are influenced by different dietary habits and geographical provenances that this study's 
population.260 Perhaps, the drastic differences in a lifelong and generation long dietary pattern 
contributes to different metabolic reactions between the two populations. Maybe it takes more 
fermented vegetable consumption and/or for a longer period of time to modulate the gut 
microflora after years of a Western diet consumption. Perhaps, the wide variations of kimchi 
that are found in Korea contribute to kimchi's repeated positive effects on metabolic markers. 
In addition to napa cabbage, Korean kimchi may contain garlic, red chili, seaweed, green leek, 
ginger, leaf mustard, sweet potato, radish, dropwort, wild grasses, lettuce, cucumber, eggplant, 
pumpkin, and/or burdock to name a few.309 Additionally, the Korean study interventions used 
between 180 to 300 g of fermented kimchi as compared to 100 g that recommended in our 
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study.183,203,310,311 Moreover, two out of three kimchi studies used intervention diets planned by 
a dietitian rather than having the participants follow their baseline diet as we did in this study, 
which may have contributed to positive results from the effects of both fresh and fermented 
kimchi.183,310,311 For example, Choi et al183 investigated the effects fermented kimchi on 100 
participants; 50 participants consumed 210 g per day and 50 participants consumed 15 g per 
day for seven days, while participants from both groups consumed the same diets that were 
created by a dietitian. Both groups showed improved fasting blood glucose, total glucose, total 
cholesterol, low density lipoprotein cholesterol, serum lipid levels, and total antioxidant levels; 
however, the effects were more profound among the high kimchi group. A four-week crossover 
trial by Kim et al,202 compared the effects of fresh versus fermented kimchi consumption on 
44 participants who were randomly assigned to either 300 g per day of fresh kimchi (n=22) or 
300 g per day of fermented kimchi (n=22). Both groups were asked to follow the same diet that 
was created by a dietitian. Both groups demonstrated significant improvements in body weight, 
BMI, and body fat; however, the fermented kimchi group also demonstrated significant 
improvements in waist-to-hip ratio, fasting blood glucose, and fasting insulin levels. 
4.3.  Challenges 
Recruitment of participants was a major challenge. This was mostly due to availability of 
research assistants who were able to commit time to communicate with potential study 
participants. Adequate staff was needed for duties such as help with recruitment and on-
campus participant visits. Furthermore, potential participants who met the study criteria did 
not participate because they did not like needles, were not willing to drive to UNF three times 
in six weeks, and/or were challenged with compliance of consuming the recommended 
amount of vegetables. The fact that participants could only receive up to $30 compensation 




During the review process, there were a limited number of publications that contained 
information on fermented vegetables, associated metabolic pathways, and their effect on 
inflammation and metabolic disease. Studies that were conducted to establish the health 
benefits of these live microorganisms were mostly performed in mice and murine cell lines, 
while human subject studies were often limited to small sample sizes and frequently produces 
inconsistent results. Thus, it is difficult to adequately report the effects of fermented vegetables 
consumption on microbiota composition, inflammation, and mechanisms of actions on disease 
pathogenesis. Furthermore, most research on this topic has been conducted in Asian countries 
where fermented vegetables are widely consumed and in much larger quantities as compared 
to the typical consumption of fermented vegetables in the United States. Also, the studies of 
Asian origin used kimchi as the main source of the fermented vegetables rather than other 
fermented vegetables such as sauerkraut and pickles of different origins that contain different 
bacteria strains; thus, have different effects. The lack of research on this topic, particularly in 
the United States, leaves high variability to determine a study’s needed population size, 
vegetable type, and vegetable amount required to show a significant effect. Capturing the 
complexity of pathways between diet, the microbiome, and disease pathogenesis remains a 
challenge to be tackled, particularly when so many additional co-founding factors exists. While 
increased microbial diversity remains a hallmark for optimal health, further research is needed 
to define the best microbiota composition and how to achieve that profile. 
4.4.  Strengths  
Due to the high, world-wide, prevalence of diseases associated with poor dietary habits, 
dysbiosis, and inflammation,19,20,50,71,172 further research is needed to find effective strategies 
to combat their prevalence rates, and regular consumption of fermented vegetables may prove 
to be a helpful strategy. Not only was this study unique among the limited amount of 
comparable research, but it was also innovative because it included positive control group to 
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help differentiate effects of probiotic consumption from other vegetable benefits such as fiber, 
vitamin, and prebiotic delivery. Moreover, this study tested the feasibility of regular 
consumption of fermented vegetables and tried to be realistic with the amount of fermented 
vegetables provided to study participants, considering that fermented vegetables are commonly 
present in the American diet. This study included a comprehensive array of variables measured 
based off similar microbiota research that reported their correlation to diet and inflammation. 
This pilot and feasibility study contributes to the limited body of knowledge related to the role 
of fermented vegetables on health outcomes of Western cultures. 
4.5.  Limitations  
Limitation of our pilot and feasibility study include a small sample size, using only women 
participants who were mostly of Caucasian decent, and the exclusion of those with bowel 
disease are a few limitations. Specifically, our convenience sample obtained in Jacksonville 
Florida does not accurately represent cultural diversity. The subjects would have been 
compared to themselves using their baseline and end results; therefore, it would be possible 
to include more variety of subjects. As mentioned in the literature review, the diversity of the 
gut microbiota increases from birth to about age 12 whereby it remains stable through 
adulthood, and then decreases with older age.13 This relationship between age and 
microbiome diversity presents a limitation when comparing results due to the wide age range 
(18-69 years) of the participants. Also, this study used normal weight, overweight, and obese 
participants with BMIs ranging from 18-44, which may have introduced more variability in 
the findings, given that normal weight women have been reported to have a more favorable 
gut microbiota compositions at baseline as compared to their overweight/obese 
counterparts;63,312 however, the Western-type diet may override the effects of weight on gut 
microflora profiles.313 The use of food and gastrointestinal surveys is yet another limitation 
due the nature of their subjectivity. Moreover, some participants may have incorporated 
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additional cofounding variables because they decided to start eating significantly healthier 
and/or living a healthier lifestyle such as adding a significant amount of physical activity; 
thus, affecting the intestinal microbiome.  
4.6.  Conclusion 
The human gut houses trillions of microorganisms that compose a dynamic ecosystem unique 
to everyone. Diet, genetics, environment, lifestyle, and antibiotic use significantly shape the 
gut microbial composition. Dysbiosis is correlated to increased inflammation and metabolic 
disease. Recently, consumption of fermented vegetables has emerged as a possible strategy to 
help reduce dysbiosis. Fermented foods were among the first processed food products that 
humans consumed. In addition to preservation, fermentation increases the food’s ability to 
synthesize vitamins and enzymes while enhancing the flavor, texture, nutritional quality, and 
functionality of the food that contribute to the host’s well-being. Lactobacillus strains and are 
among the predominant bacteria found in fermented vegetables and play pivotal role in gut 
homeostasis. A proposed mechanism of action through which the live microorganisms in 
fermented vegetables act is through a reduction of inflammatory processes in the gut via a 
decrease in the signaling associated with the NF-B signaling pathway as well as the 
attenuation of the release of pro-inflammatory cytokines. The health benefits of consuming 
fermented vegetables have been demonstrated in a limited number of studies that used human 
subjects; nonetheless, they are perceived as good sources of beneficial, functional organisms 
that have a significant impact on health and disease; therefore, it is recommended to feed the 
microbiome accordingly. It is imperative to carry out more studies not only on the effects of 
consuming fermented vegetables on gut composition and disease, but also to identify the 
metabolic pathways and biomarkers associated with diet and disease. Modulation of gut 
microbiota is considered the first target to establish probiotic efficacy in a healthy population. 
Understanding of the relationship of diet and the gut microbiome is vital for the development 
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of personalized medicine, food products, eating patterns, and other therapeutic strategies to 
help combat the global burden of non-communicable diseases. More randomized control trials 
and large cohort are needed to better understand the interactions between the microbiome and 
diet, environment, genetics, and lifestyle to discover evidence of the effects of fermented 
vegetable consumption on inflammation and gut microbiota composition.  
Some this study’s strengths include a positive control group, randomized study design, 
and comprehensive array of variables based on research that reported correlations between 
these variables and inflammation and/or gut microflora. Limitations of this study were a small 
sample size, use of a FFQ, use of only women participants who were mostly of Caucasian 
decent and obtained in Jacksonville Florida, a wide age range, and a wide weight range. 
However, the primary objective of this pilot and feasibility study was to explore the feasibility 
of fermented vegetable consumption for six weeks on markers of inflammation and gut 
microflora profiles in women. Indeed, we found one high and 27 medium significant 
correlations that are in agreement with similar studies that included a positive correlation 
between age and Lachnospiraceae, age and Bifidobacterium, vitamins B2 and B12 and 
Bifidobacterium; vitamin B1 and Roseburia, fiber and Clostridiales, and negative correlations 
between Prevotella and total protein, animal protein, cholesterol, and SFAs. Moreover, we 
found an upward trend in the Shannon index, a significant increase in the anti-inflammatory 
bacteria, Faecalibacterium prausnitzii, and a decrease in pro-inflammatory bacteria, 
Ruminococcus torques, at timepoint 2 among Group A at timepoint 2 that may be related to 
fermented vegetable consumption. Future larger randomized controlled trials are needed to 
determine the precise effects of fermented vegetable consumption on metabolic markers and 
gut microflora. Our next step will be to obtain three stool samples per participant per timepoint 
to reduce the limitations of having a small sample size. It is also important to obtain an optimal 
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Chapter Five: Implications for Practice 
5.1. Nutritional implications 
The nutritional implications of the consumption of fermented vegetables on the composition 
of the intestinal microflora are diverse. It is important to note that whether fermented or not, 
many vegetables contain prebiotics that promote increased probiotic growth; thus, increasing 
nutritional benefits.314 Microorganisms present in fermented vegetables release various 
enzymes and produce vitamins such as B and K vitamins in the intestinal gut.315 
Microorganisms present in fermented vegetables have been known to increase the expression 
of the main calcium ion transporter in intestinal epithelial cells thereby increasing the calcium 
pools in the gut resulting in strong teeth and bones. Microorganisms in fermented vegetables 
have been shown to also increase the availability of vitamin D in the enterocytes of the gut.167 
Hydrolysis of these microorganisms may enhance protein and fat bioavailability as well as 
induce the production of free amino acids, SCFAs, lactic acid, propionic acid, and butyric acid 
that aid in increasing the energy pool of the host individual.316 They also have been known to 
improve the digestion of certain food components. Lactobacillus acidophilus has been known 
to release lactase that aids in the digestion of lactose, thereby reducing the symptoms of lactose 
indigestion in lactose-intolerant individuals.317 The potential of fermented vegetable 
consumption on the prevention and improvement of many health concerns is significant. As 
more studies confirm the health benefits of fermented vegetables, a need for nutrition education 
will increase.  
Fermented vegetables pose a food-drug interaction with monoamine oxidase inhibitors 
(MAOIs) due to the high levels of tyramine in fermented foods. Consumption of foods high in 
tyramine while taking an MAOI can result in dangerous levels of tyramine and can cause 
increased blood pressure that may require emergency treatment. In addition, the high levels of 
sodium in the brine solution that is required for fermentation to occur may also increase blood 
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pressure among those who are salt sensitive. A low tyramine may be needed.318 Per the 
Academy of Nutrition and Dietetics (AND),319 a tyramine-restricted diet recommends to avoid 
fermented and aged foods. No specific tyramine amount was given, but the AND did 
recommend foods to eat and not to eat. The recommended foods are grains; fresh, frozen, or 
canned fruit and vegetables; pasteurized dairy; and fresh meats and fish. Foods to limit are 
alcohol and caffeinated beverages such as coffee and cola. Foods to avoid are fermented 
vegetables such as sauerkraut and kimchi; decomposed or spoiled fruit and vegetables; aged 
cheese such as cheddar and gouda; fermented meats such as corned beef and chorizo; wine and 
beer; and fermented soy products such as soy sauce and soybean curd. Also, it was recommend 
not to eat food that was left in the fridge for more than 24-48 hours.319 
5.2. Dietetic Implications 
Nutrition is becoming recognized as a necessity of treatment that highlights food as medicine. 
Due to the nutritional implications of fermented vegetables, there is great opportunity for 
dietitians to get involved in research that will unravel the specific benefits of fermented 
vegetables and move registered dietitians further into the forefront of medicine. RDNs could 
develop diets that are high in the desired bacteria to provide personalized nutritional 
counseling.320 For example, some strains of Lactobacilli and Bifidobacteria produce high levels 
of folate,321,322 that could someday be obtained through fermented vegetable consumption323 
and reduce the risk of B vitamin deficiencies.324 
B vitamin food fortification has drastically reduced deficiencies and conditions such as 
pellagra, beriberi,325 neural tube defects,326 and anemia.327 However, food fortification does not 
meet many populations' needs such as those with alcohol dependence, gastrointestinal diseases, 
and HIV/AIDS, in addition to the elderly, reproductive-aged women, pregnant and postpartum 
women, young children, female adolescents in low income countries, women and children in 
low-income countries such as southeast Asia and Africa, vegans, those who cannot drink milk 
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due to lactose intolerance, children in low-income countries where gastrointestinal infections 
are prevalent such as Africans and Asians, those with enhanced riboflavin excretion due to 
diabetes mellitus, trauma, stress, and oral contraceptive use remain at increased risk of 
morbidity due to B vitamin deficiencies.324,327 Perhaps, fermented foods such as fermented 
vegetables could help bridge the gap of fortification programs and help many at risk 
populations obtain adequate B vitamin intake.323,328–330   
5.3.  Policy implications 
The policy implications with regards to the health benefits of consuming fermented vegetables 
are not clearly defined. Probiotics or live microorganisms present in fermented vegetables are 
overlapping between conventional and regulatory definitions of what constitutes a food and 
what constitutes a drug.331 Regulatory agencies such as the Food and Drug Administration and 
the Federal Food, Drug, and Cosmetic Act332 that oversee food and pharmaceutical 
manufacturing consider live microorganisms in fermented vegetables as either whole food, 
enriched, or fortified foods that might have a potential beneficial effect on the health of an 
individual when consumed regularly. With regards to the study of these microorganisms and 
their implications on the treatment of specific diseases, these microorganisms in fermented 
vegetables might be viewed as medicinal food and thus subjected to regulation by the FDA.332 
Live microorganisms present in fermented vegetables might also be viewed as pharmaceutical 
drugs and regulated by the US regulatory code. 
In terms of the guidelines required for the proper use of probiotics found in fermented 
vegetables, the following dietitian guidelines should be followed:  
1. Individuals with impaired immune functions are generally required to seek specific advice 
from a licensed physician with regards to the use of these live microorganisms to alleviate 
gut disorder symptoms.333  
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2. Patients with gastrointestinal disorders such as IBS and IBD are recommended by 
registered dietitians/nutritionists to consume fermented foods with live microorganisms for 
a trial period of about four weeks in order to relieve symptoms commonly associated with 
these disorders such as diarrhea and bloating.333  
3. Patients on antibiotics are at a high risk of being contaminated with the Clostridium difficile 
bacteria that causes diarrhea in these patients. It is often recommended as a preventive 
measure to ingest probiotics which might prevent the proliferation of this bacteria in the 
gut of these patients.334 
The identification of cytological and molecular biomarkers may be utilized as screening 
tools to predict and prevent many diseases such as obesity, diabetes, and cancer. Discovering 
genetic information related to the consumption of fermented vegetables and host metabolism 
and disease development could prove vital in the understanding of the effect of probiotics, 
nutrients, and dietary factors at the molecular level.335 As the population ages and diseases 
multiply, it is imperative that various stakeholders such as the government, non-governmental 
organizations, policy makers, health providers, and dietitians take advantage of this opportunity 
to perform research in hopes of reducing inflammatory and metabolic disease prevalence. The 
development of a consensus definitions for prebiotics and probiotics by the ISAPP133 is 
beneficial for many stakeholders. These consensus definitions help reduce misinformation and 
misinterpretation among consumers and healthcare providers. This will help facilitate standard 
guidelines for scientific research, consumer-friendly and informative product labels, accurate 
marketing messages, safe product manufacturing, defined product regulations, and accurate 
information provided by healthcare professionals.336  
5.4.  Ethical implications 
The ethical implications with regards to the role of probiotics present in fermented vegetables 
and their health benefits have not been widely studied. Till date, little is known about the wider 
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public’s view on the therapeutic and health benefits of live microorganisms found in fermented 
vegetables. Individuals with gastrointestinal disorders are the target populations that can best 
answer the questions with regards to the potential benefits of this food in alleviating their 
symptoms associated with these disorders. Their opinions may provide insight into key issues 
with regards to the regulation of such foods for therapeutic purposes as well as the use of these 
foods in clinical trial research, patient care, and the need for this target population to participate 
in the informed decision-making process. Patients with gastrointestinal disorders likely expect 
more rigorous regulation of these food products in terms of low costs and low involvement of 
pharmaceutical companies that might want to market these foods specifically for this target 
population.337 
Studies should be carried out in human subjects in order to determine the health benefits 
of consuming fermented vegetables in terms of the immune response and the growth 
composition of the intestinal microflora. It is important to properly ascertain the strain of 
bacteria that is responsible for promoting immune regulation observed upon ingestion of these 
microorganisms present in fermented vegetables. Additionally, there exist several risks 
associated with the ingestion of bacterial probiotics specifically in immune-compromised 
individuals such as pregnant women, babies, and the elderly.338 The interaction of probiotic 
microorganisms present in fermented vegetables with gut commensal bacteria might have 
direct implications on the health of the host. Clinical studies are required in order to understand 
how microorganisms from fermented vegetables interact with the host gut microbiota and their 
role in the promotion of immune defense mechanisms.339 Several microorganisms in fermented 
vegetables particularly enterococci may confer and transmit antibiotic resistance to bacteria of 
the Bacillus cereus group that are known to produce enterotoxins in the gut.340 Probiotics may 
also cause systemic infections, overstimulation of the immune system, and impaired metabolic 
activities in vulnerable individuals.341 
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Controlling the microbial ecosystem from fermented food products offers great 
therapeutic alternatives for the prevention and treatment of diseases. The fact that the ingestion 
of probiotic microorganisms has great implications in improving the health of individuals and 
preventing certain diseases is gaining traction. However, the term probiotic has been loosely 
used and has led to the overpromotion of the health benefits of these microorganisms without 
reliable data in human subjects to prove such findings. 
5.5.  Future Directions 
Continued development of full shotgun metagenomics sequencing of the genomes of 
untargeted cells in a community provides community composition and function that allows for 
greater taxonomy identification and profiling; thus, increasing human understanding of the 
mechanisms and cross-talk between the gut microbiome and disease. Currently, this method is 
limited due to the high cost and the technology needed to host DNA interference. 16S mRNA 
amplicon sequencing identifies microbes but does not provide microbial function. Next 
generation sequencing such as, shotgun metagenomics, provides gene composition in addition 
to microbial identity. Shotgun metagenomics reveals genes that are encoded by certain bacteria 
providing a deeper understanding of the mechanisms between bacteria and disease.342 
Food-grade cloning vectors that genetically modify food-grade probiotics could 
become industrialized.343–345 Also, genetic modification of probiotics as delivery vehicles for 
bioactive compounds or antigens could provide targeted, disease-specific, delivery of 
therapeutic molecules.346  Perhaps probiotics that are genetically created could be added to 
many common, non-fermented foods that allows humans to safely and easily consume desired 
levels of various health-promoting probiotics. People in developed and developing countries 
could benefit from probiotic products and foods to help fight against disease. Future research 
paves the way for biotechnology companies to market personalized microbiome testing and 
could lead to microbiome-based health screenings. Dietary supplementation of specific 
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bacteria in therapeutic doses may prove to be a preferred method for targeted, health therapies, 
as compared with consumption of adequate bacteria through food intake. Standardization of 
future guidelines for product development and food labeling will be essential.  
Vitamin-producing bacteria provide a new perspective and hope of a more consumer-
friendly vitamin fortification process than synthesized vitamins; however, more research is 
needed to determine dosing, absorption, and production of vitamin-producing bacteria. The 
use of vitamin-producing bacteria may provide an organic, marketable solution that adds 
nutrition value to fermented products for people obtain vitamin Recommended Daily Intake 
values. This could help people save money on synthesized vitamins in addition to reducing 
the risk of vitamin toxicity. Precision medicine is an attractive approach for disease therapy, 
but further understanding of the interplay between genes, phenotypes, and the microbiome is 
needed. Lastly, ideas for future studies include: 
• A follow-up article that examines case presentations may discover further findings by 
analyzing specific variables unique to the individual. The results of this study were 
reported for averaged outcomes per group. It would be interesting to see participant 
results on the individual level.  
• US conducted feeding trials that compare fermented kimchi to other fermented 
vegetables to obtain feasible amounts needed of various fermented vegetables for 
effective gut microbiota modulation among people in the US. Kimchi may be a more 
potent fermented vegetable as compared to fermented pickles and fermented 
sauerkraut and may be more feasible for many Americans to consume if smaller 
amounts are needed for microbiota change. 
• Feeding trials that examine the effects of fermented vegetable consumption of 
dysbiosis and disease. 
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• Studies that obtain three stool samples per participant per timepoint to increase the 
data pool and to discover fluctuations among individual stool microflora.  
• Studies that investigate vitamin B and K uptake and absorption from fermented 
vegetable consumption to decipher if fermented vegetable consumption is a feasible 
method to help high risk populations that suffer from these vitamin deficiencies. 
• Fermented vegetable feeding trials that exclude salt sensitive subjects to control for 






















Figure S1: Phylum-Diet: Firmicutes is the predominant phyla across all vegetable types, with 
the non-fermented sauerkraut having the greatest relative abundance at 82.9% followed by 
fermented sauerkraut (relative abundance 63.5%), non-fermented pickles (relative abundance 
49.8%), and fermented pickles (relative abundance 34.1%). BP (non-fermented pickles), BS 






Figure S2: Genus-Diet: Bacillales is the predominant genus for the BP (relative abundance 
40%) and BS (relative abundance 63.7%). Lactobacillus is the predominant genus for the AP 
(relative abundance 28.8%) and AS (relative abundance 25.4%). BP (non-fermented pickles), 




Figure S3. Shannon Index-Diet 





Figure S4. Observed OTUs-Diet 











Figure S5: Top OTUs-Diet 
 
 
BP (non-fermented pickles), BS (non-fermented sauerkraut), AP (fermented pickles), AS 
(fermented sauerkraut) 
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